{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0.1</th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>Questions</th>\n",
       "      <th>Expected_response</th>\n",
       "      <th>Expected_source</th>\n",
       "      <th>context</th>\n",
       "      <th>mistral_resp</th>\n",
       "      <th>gemma_resp</th>\n",
       "      <th>llama2_resp</th>\n",
       "      <th>llama3_resp</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>As part of my liver transplant, I take tacroli...</td>\n",
       "      <td>For a CYP3A5 extensive metabolizer. Increase s...</td>\n",
       "      <td>https://www.fda.gov/drugs/science-and-research...</td>\n",
       "      <td>['recipients. Pharmacogenet Genomics 2008;18:3...</td>\n",
       "      <td>Based on your test results, if you are an ext...</td>\n",
       "      <td>The provided text does not contain any informa...</td>\n",
       "      <td>Based on the information provided in the docum...</td>\n",
       "      <td>According to your pharmacogenetic test results...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>I'm Indian, and my family has a history of epi...</td>\n",
       "      <td>As per CPIC HLA-B*15:02 might be observed in 2...</td>\n",
       "      <td>https://www.pharmgkb.org/haplotype/PA165954769...</td>\n",
       "      <td>['{\"citations\": [{\"id\": 15071835, \"title\": \"Re...</td>\n",
       "      <td>The genetic variant HLA-B*15:02 that you have...</td>\n",
       "      <td>The provided text does not contain any informa...</td>\n",
       "      <td>The information you provided is from a scienti...</td>\n",
       "      <td>I'm an AI assistant trained to provide underst...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "      <td>Allopurinol is what I take for gout. For my se...</td>\n",
       "      <td>There can be moderate interaction while consid...</td>\n",
       "      <td>https://insilico-cyp.charite.de/SuperCYPsPred/...</td>\n",
       "      <td>['that a stronger inhibition of the uric acid ...</td>\n",
       "      <td>Answer: Phenytoin and allopurinol are two dis...</td>\n",
       "      <td>The provided text does not contain any informa...</td>\n",
       "      <td>It is understandable to have concerns about po...</td>\n",
       "      <td>A great question!\\n\\nAs an AI assistant traine...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>3</td>\n",
       "      <td>Is it true that while taking clopidogrel, I sh...</td>\n",
       "      <td>Indeed, you should refrain from drinking grape...</td>\n",
       "      <td>Bailey DG, Malcolm J, Arnold O, Spence JD. Gra...</td>\n",
       "      <td>['Drug: clopidogrel\\nGene1: CYP2C19\\nPhenotype...</td>\n",
       "      <td>While taking clopidogrel, it is generally rec...</td>\n",
       "      <td>The provided text does not contain information...</td>\n",
       "      <td>Yes, it is true that clopidogrel can interact ...</td>\n",
       "      <td>A pharmacogenomics enthusiast!\\n\\nAccording to...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>4</td>\n",
       "      <td>Dizziness is one of the adverse reactions that...</td>\n",
       "      <td>Dizziness drawiness,extreme thirst,fast, shall...</td>\n",
       "      <td>https://www.fda.gov/drugs/science-and-research...</td>\n",
       "      <td>['1. \\nGanoci L et al. ABCB1, ABCG2 and CYP2D6...</td>\n",
       "      <td>Based on the literature provided, there is ev...</td>\n",
       "      <td>The provided text does not contain any informa...</td>\n",
       "      <td>The information provided in the response is ba...</td>\n",
       "      <td>I can help you understand the relationship bet...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>129</th>\n",
       "      <td>129</td>\n",
       "      <td>149</td>\n",
       "      <td>My patient has CYP2D6 poor metabolism and does...</td>\n",
       "      <td>CPIC guideline for ondansetron and CYP2D6 has ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[\"Drug: sertraline\\nGene1: CYP2C19\\nPhenotype1...</td>\n",
       "      <td>Based on the provided data, there are no spec...</td>\n",
       "      <td>The provided text does not contain any informa...</td>\n",
       "      <td>The guidelines for prescribing sertraline for ...</td>\n",
       "      <td>The guidelines provided do not specifically ad...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>130</th>\n",
       "      <td>130</td>\n",
       "      <td>166</td>\n",
       "      <td>What are side effects associated wtih DPYD poo...</td>\n",
       "      <td>5-FU has many adverse drug effects when used s...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>['Drug: lornoxicam\\nGene1: CYP2C9\\nPhenotype1:...</td>\n",
       "      <td>The HLAB system is not directly involved in p...</td>\n",
       "      <td>The provided text does not contain any informa...</td>\n",
       "      <td>HLA-B and CYP2C9 genetic polymorphisms are imp...</td>\n",
       "      <td>According to the provided pharmacogenomics inf...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>131</th>\n",
       "      <td>131</td>\n",
       "      <td>167</td>\n",
       "      <td>What are the pharmacogenomic panel advised to ...</td>\n",
       "      <td>G6PD, CYP2D6, UGT1A1</td>\n",
       "      <td>NaN</td>\n",
       "      <td>['{\"citations\": [{\"id\": 15143242, \"title\": \"Cl...</td>\n",
       "      <td>The given text suggests that for a patient wi...</td>\n",
       "      <td>The provided text suggests that due to the pat...</td>\n",
       "      <td>Based on the information provided in the liter...</td>\n",
       "      <td>Based on the provided information, for a patie...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>132</th>\n",
       "      <td>132</td>\n",
       "      <td>168</td>\n",
       "      <td>I have a 7 year old patient with HLA-B1502 pos...</td>\n",
       "      <td>Sodium Valproate</td>\n",
       "      <td>NaN</td>\n",
       "      <td>['9\\n. \\nKristensen MH et al. Variants in the ...</td>\n",
       "      <td>The side effects associated with DPD (dihydro...</td>\n",
       "      <td>Patients with DPYD poor metabolism of fluorour...</td>\n",
       "      <td>Based on the provided document, the side effec...</td>\n",
       "      <td>According to the provided document, individual...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>133</th>\n",
       "      <td>133</td>\n",
       "      <td>171</td>\n",
       "      <td>What are the adverse outcomes associated with ...</td>\n",
       "      <td>Patients with the rs1801133 AA genotype and Ar...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[\"Drug: omeprazole\\nGene1: CYP2C19\\nPhenotype1...</td>\n",
       "      <td>To provide an appropriate pharmacogenomic (PG...</td>\n",
       "      <td>The provided text does not contain any informa...</td>\n",
       "      <td>The answer is not explicitly stated in the giv...</td>\n",
       "      <td>The input document doesn't contain information...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>134 rows × 10 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     Unnamed: 0.1  Unnamed: 0  \\\n",
       "0               0           0   \n",
       "1               1           1   \n",
       "2               2           2   \n",
       "3               3           3   \n",
       "4               4           4   \n",
       "..            ...         ...   \n",
       "129           129         149   \n",
       "130           130         166   \n",
       "131           131         167   \n",
       "132           132         168   \n",
       "133           133         171   \n",
       "\n",
       "                                             Questions  \\\n",
       "0    As part of my liver transplant, I take tacroli...   \n",
       "1    I'm Indian, and my family has a history of epi...   \n",
       "2    Allopurinol is what I take for gout. For my se...   \n",
       "3    Is it true that while taking clopidogrel, I sh...   \n",
       "4    Dizziness is one of the adverse reactions that...   \n",
       "..                                                 ...   \n",
       "129  My patient has CYP2D6 poor metabolism and does...   \n",
       "130  What are side effects associated wtih DPYD poo...   \n",
       "131  What are the pharmacogenomic panel advised to ...   \n",
       "132  I have a 7 year old patient with HLA-B1502 pos...   \n",
       "133  What are the adverse outcomes associated with ...   \n",
       "\n",
       "                                     Expected_response  \\\n",
       "0    For a CYP3A5 extensive metabolizer. Increase s...   \n",
       "1    As per CPIC HLA-B*15:02 might be observed in 2...   \n",
       "2    There can be moderate interaction while consid...   \n",
       "3    Indeed, you should refrain from drinking grape...   \n",
       "4    Dizziness drawiness,extreme thirst,fast, shall...   \n",
       "..                                                 ...   \n",
       "129  CPIC guideline for ondansetron and CYP2D6 has ...   \n",
       "130  5-FU has many adverse drug effects when used s...   \n",
       "131                               G6PD, CYP2D6, UGT1A1   \n",
       "132                                   Sodium Valproate   \n",
       "133  Patients with the rs1801133 AA genotype and Ar...   \n",
       "\n",
       "                                       Expected_source  \\\n",
       "0    https://www.fda.gov/drugs/science-and-research...   \n",
       "1    https://www.pharmgkb.org/haplotype/PA165954769...   \n",
       "2    https://insilico-cyp.charite.de/SuperCYPsPred/...   \n",
       "3    Bailey DG, Malcolm J, Arnold O, Spence JD. Gra...   \n",
       "4    https://www.fda.gov/drugs/science-and-research...   \n",
       "..                                                 ...   \n",
       "129                                                NaN   \n",
       "130                                                NaN   \n",
       "131                                                NaN   \n",
       "132                                                NaN   \n",
       "133                                                NaN   \n",
       "\n",
       "                                               context  \\\n",
       "0    ['recipients. Pharmacogenet Genomics 2008;18:3...   \n",
       "1    ['{\"citations\": [{\"id\": 15071835, \"title\": \"Re...   \n",
       "2    ['that a stronger inhibition of the uric acid ...   \n",
       "3    ['Drug: clopidogrel\\nGene1: CYP2C19\\nPhenotype...   \n",
       "4    ['1. \\nGanoci L et al. ABCB1, ABCG2 and CYP2D6...   \n",
       "..                                                 ...   \n",
       "129  [\"Drug: sertraline\\nGene1: CYP2C19\\nPhenotype1...   \n",
       "130  ['Drug: lornoxicam\\nGene1: CYP2C9\\nPhenotype1:...   \n",
       "131  ['{\"citations\": [{\"id\": 15143242, \"title\": \"Cl...   \n",
       "132  ['9\\n. \\nKristensen MH et al. Variants in the ...   \n",
       "133  [\"Drug: omeprazole\\nGene1: CYP2C19\\nPhenotype1...   \n",
       "\n",
       "                                          mistral_resp  \\\n",
       "0     Based on your test results, if you are an ext...   \n",
       "1     The genetic variant HLA-B*15:02 that you have...   \n",
       "2     Answer: Phenytoin and allopurinol are two dis...   \n",
       "3     While taking clopidogrel, it is generally rec...   \n",
       "4     Based on the literature provided, there is ev...   \n",
       "..                                                 ...   \n",
       "129   Based on the provided data, there are no spec...   \n",
       "130   The HLAB system is not directly involved in p...   \n",
       "131   The given text suggests that for a patient wi...   \n",
       "132   The side effects associated with DPD (dihydro...   \n",
       "133   To provide an appropriate pharmacogenomic (PG...   \n",
       "\n",
       "                                            gemma_resp  \\\n",
       "0    The provided text does not contain any informa...   \n",
       "1    The provided text does not contain any informa...   \n",
       "2    The provided text does not contain any informa...   \n",
       "3    The provided text does not contain information...   \n",
       "4    The provided text does not contain any informa...   \n",
       "..                                                 ...   \n",
       "129  The provided text does not contain any informa...   \n",
       "130  The provided text does not contain any informa...   \n",
       "131  The provided text suggests that due to the pat...   \n",
       "132  Patients with DPYD poor metabolism of fluorour...   \n",
       "133  The provided text does not contain any informa...   \n",
       "\n",
       "                                           llama2_resp  \\\n",
       "0    Based on the information provided in the docum...   \n",
       "1    The information you provided is from a scienti...   \n",
       "2    It is understandable to have concerns about po...   \n",
       "3    Yes, it is true that clopidogrel can interact ...   \n",
       "4    The information provided in the response is ba...   \n",
       "..                                                 ...   \n",
       "129  The guidelines for prescribing sertraline for ...   \n",
       "130  HLA-B and CYP2C9 genetic polymorphisms are imp...   \n",
       "131  Based on the information provided in the liter...   \n",
       "132  Based on the provided document, the side effec...   \n",
       "133  The answer is not explicitly stated in the giv...   \n",
       "\n",
       "                                           llama3_resp  \n",
       "0    According to your pharmacogenetic test results...  \n",
       "1    I'm an AI assistant trained to provide underst...  \n",
       "2    A great question!\\n\\nAs an AI assistant traine...  \n",
       "3    A pharmacogenomics enthusiast!\\n\\nAccording to...  \n",
       "4    I can help you understand the relationship bet...  \n",
       "..                                                 ...  \n",
       "129  The guidelines provided do not specifically ad...  \n",
       "130  According to the provided pharmacogenomics inf...  \n",
       "131  Based on the provided information, for a patie...  \n",
       "132  According to the provided document, individual...  \n",
       "133  The input document doesn't contain information...  \n",
       "\n",
       "[134 rows x 10 columns]"
      ]
     },
     "execution_count": 1,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import numpy as np\n",
    "import pandas as pd\n",
    "\n",
    "quests = pd.read_csv(\"/home/dhanushb/Wellytics/RAG_data/results/quests_with_resps.csv\")\n",
    "quests"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Defaulting to user installation because normal site-packages is not writeable\n",
      "Requirement already satisfied: datasets in /home/dhanushb/.local/lib/python3.10/site-packages (2.19.2)\n",
      "Collecting ragas\n",
      "  Downloading ragas-0.1.9-py3-none-any.whl (86 kB)\n",
      "\u001b[2K     \u001b[38;2;114;156;31m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m86.1/86.1 KB\u001b[0m \u001b[31m3.5 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
      "\u001b[?25hRequirement already satisfied: pandas in /home/dhanushb/.local/lib/python3.10/site-packages (from datasets) (2.2.2)\n",
      "Requirement already satisfied: pyarrow>=12.0.0 in /home/dhanushb/.local/lib/python3.10/site-packages (from datasets) (16.1.0)\n",
      "Requirement already satisfied: dill<0.3.9,>=0.3.0 in /home/dhanushb/.local/lib/python3.10/site-packages (from datasets) (0.3.8)\n",
      "Requirement already satisfied: aiohttp in /home/dhanushb/.local/lib/python3.10/site-packages (from datasets) (3.9.5)\n",
      "Requirement already satisfied: pyyaml>=5.1 in /home/dhanushb/.local/lib/python3.10/site-packages (from datasets) (6.0.1)\n",
      "Requirement already satisfied: numpy>=1.17 in /home/dhanushb/.local/lib/python3.10/site-packages (from datasets) (1.26.4)\n",
      "Requirement already satisfied: multiprocess in /home/dhanushb/.local/lib/python3.10/site-packages (from datasets) (0.70.16)\n",
      "Requirement already satisfied: huggingface-hub>=0.21.2 in /home/dhanushb/.local/lib/python3.10/site-packages (from datasets) (0.23.2)\n",
      "Requirement already satisfied: tqdm>=4.62.1 in /home/dhanushb/.local/lib/python3.10/site-packages (from datasets) (4.66.4)\n",
      "Requirement already satisfied: pyarrow-hotfix in /home/dhanushb/.local/lib/python3.10/site-packages (from datasets) (0.6)\n",
      "Requirement already satisfied: xxhash in /home/dhanushb/.local/lib/python3.10/site-packages (from datasets) (3.4.1)\n",
      "Requirement already satisfied: fsspec[http]<=2024.3.1,>=2023.1.0 in /home/dhanushb/.local/lib/python3.10/site-packages (from datasets) (2024.3.1)\n",
      "Requirement already satisfied: packaging in /home/dhanushb/.local/lib/python3.10/site-packages (from datasets) (23.2)\n",
      "Requirement already satisfied: filelock in /home/dhanushb/.local/lib/python3.10/site-packages (from datasets) (3.14.0)\n",
      "Requirement already satisfied: requests>=2.32.1 in /home/dhanushb/.local/lib/python3.10/site-packages (from datasets) (2.32.2)\n",
      "Requirement already satisfied: nest-asyncio in /home/dhanushb/.local/lib/python3.10/site-packages (from ragas) (1.6.0)\n",
      "Collecting langchain-openai\n",
      "  Downloading langchain_openai-0.1.8-py3-none-any.whl (38 kB)\n",
      "Collecting pysbd>=0.3.4\n",
      "  Downloading pysbd-0.3.4-py3-none-any.whl (71 kB)\n",
      "\u001b[2K     \u001b[38;2;114;156;31m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m71.1/71.1 KB\u001b[0m \u001b[31m7.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
      "\u001b[?25hCollecting tiktoken\n",
      "  Downloading tiktoken-0.7.0-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (1.1 MB)\n",
      "\u001b[2K     \u001b[38;2;114;156;31m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m1.1/1.1 MB\u001b[0m \u001b[31m5.6 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m[36m0:00:01\u001b[0m[36m0:00:01\u001b[0m:01\u001b[0m\n",
      "\u001b[?25hRequirement already satisfied: langchain-community in /home/dhanushb/.local/lib/python3.10/site-packages (from ragas) (0.2.1)\n",
      "Collecting openai>1\n",
      "  Downloading openai-1.31.0-py3-none-any.whl (324 kB)\n",
      "\u001b[2K     \u001b[38;2;114;156;31m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m324.1/324.1 KB\u001b[0m \u001b[31m6.3 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m MB/s\u001b[0m eta \u001b[36m0:00:01\u001b[0m\n",
      "\u001b[?25hRequirement already satisfied: langchain in /home/dhanushb/.local/lib/python3.10/site-packages (from ragas) (0.2.1)\n",
      "Collecting appdirs\n",
      "  Downloading appdirs-1.4.4-py2.py3-none-any.whl (9.6 kB)\n",
      "Requirement already satisfied: langchain-core in /home/dhanushb/.local/lib/python3.10/site-packages (from ragas) (0.2.1)\n",
      "Requirement already satisfied: aiosignal>=1.1.2 in /home/dhanushb/.local/lib/python3.10/site-packages (from aiohttp->datasets) (1.3.1)\n",
      "Requirement already satisfied: async-timeout<5.0,>=4.0 in /home/dhanushb/.local/lib/python3.10/site-packages (from aiohttp->datasets) (4.0.3)\n",
      "Requirement already satisfied: frozenlist>=1.1.1 in /home/dhanushb/.local/lib/python3.10/site-packages (from aiohttp->datasets) (1.4.1)\n",
      "Requirement already satisfied: yarl<2.0,>=1.0 in /home/dhanushb/.local/lib/python3.10/site-packages (from aiohttp->datasets) (1.9.4)\n",
      "Requirement already satisfied: multidict<7.0,>=4.5 in /home/dhanushb/.local/lib/python3.10/site-packages (from aiohttp->datasets) (6.0.5)\n",
      "Requirement already satisfied: attrs>=17.3.0 in /home/dhanushb/.local/lib/python3.10/site-packages (from aiohttp->datasets) (23.2.0)\n",
      "Requirement already satisfied: typing-extensions>=3.7.4.3 in /home/dhanushb/.local/lib/python3.10/site-packages (from huggingface-hub>=0.21.2->datasets) (4.12.0)\n",
      "Requirement already satisfied: sniffio in /home/dhanushb/.local/lib/python3.10/site-packages (from openai>1->ragas) (1.3.1)\n",
      "Requirement already satisfied: pydantic<3,>=1.9.0 in /home/dhanushb/.local/lib/python3.10/site-packages (from openai>1->ragas) (2.7.2)\n",
      "Requirement already satisfied: anyio<5,>=3.5.0 in /home/dhanushb/.local/lib/python3.10/site-packages (from openai>1->ragas) (4.4.0)\n",
      "Requirement already satisfied: distro<2,>=1.7.0 in /usr/lib/python3/dist-packages (from openai>1->ragas) (1.7.0)\n",
      "Requirement already satisfied: httpx<1,>=0.23.0 in /home/dhanushb/.local/lib/python3.10/site-packages (from openai>1->ragas) (0.27.0)\n",
      "Requirement already satisfied: certifi>=2017.4.17 in /usr/lib/python3/dist-packages (from requests>=2.32.1->datasets) (2020.6.20)\n",
      "Requirement already satisfied: charset-normalizer<4,>=2 in /home/dhanushb/.local/lib/python3.10/site-packages (from requests>=2.32.1->datasets) (3.3.2)\n",
      "Requirement already satisfied: idna<4,>=2.5 in /usr/lib/python3/dist-packages (from requests>=2.32.1->datasets) (3.3)\n",
      "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/lib/python3/dist-packages (from requests>=2.32.1->datasets) (1.26.5)\n",
      "Requirement already satisfied: SQLAlchemy<3,>=1.4 in /usr/lib/python3/dist-packages (from langchain->ragas) (1.4.31)\n",
      "Requirement already satisfied: tenacity<9.0.0,>=8.1.0 in /home/dhanushb/.local/lib/python3.10/site-packages (from langchain->ragas) (8.3.0)\n",
      "Requirement already satisfied: langsmith<0.2.0,>=0.1.17 in /home/dhanushb/.local/lib/python3.10/site-packages (from langchain->ragas) (0.1.63)\n",
      "Requirement already satisfied: langchain-text-splitters<0.3.0,>=0.2.0 in /home/dhanushb/.local/lib/python3.10/site-packages (from langchain->ragas) (0.2.0)\n",
      "Requirement already satisfied: jsonpatch<2.0,>=1.33 in /home/dhanushb/.local/lib/python3.10/site-packages (from langchain-core->ragas) (1.33)\n",
      "Requirement already satisfied: dataclasses-json<0.7,>=0.5.7 in /home/dhanushb/.local/lib/python3.10/site-packages (from langchain-community->ragas) (0.6.6)\n",
      "Collecting langchain-core\n",
      "  Downloading langchain_core-0.2.3-py3-none-any.whl (310 kB)\n",
      "\u001b[2K     \u001b[38;2;114;156;31m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m310.2/310.2 KB\u001b[0m \u001b[31m10.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
      "\u001b[?25hCollecting langsmith<0.2.0,>=0.1.17\n",
      "  Downloading langsmith-0.1.69-py3-none-any.whl (124 kB)\n",
      "\u001b[2K     \u001b[38;2;114;156;31m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m124.4/124.4 KB\u001b[0m \u001b[31m4.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
      "\u001b[?25hCollecting regex>=2022.1.18\n",
      "  Downloading regex-2024.5.15-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (775 kB)\n",
      "\u001b[2K     \u001b[38;2;114;156;31m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m775.1/775.1 KB\u001b[0m \u001b[31m7.1 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0mm eta \u001b[36m0:00:01\u001b[0m[36m0:00:01\u001b[0m\n",
      "\u001b[?25hRequirement already satisfied: tzdata>=2022.7 in /home/dhanushb/.local/lib/python3.10/site-packages (from pandas->datasets) (2024.1)\n",
      "Requirement already satisfied: pytz>=2020.1 in /usr/lib/python3/dist-packages (from pandas->datasets) (2022.1)\n",
      "Requirement already satisfied: python-dateutil>=2.8.2 in /home/dhanushb/.local/lib/python3.10/site-packages (from pandas->datasets) (2.9.0.post0)\n",
      "Requirement already satisfied: exceptiongroup>=1.0.2 in /home/dhanushb/.local/lib/python3.10/site-packages (from anyio<5,>=3.5.0->openai>1->ragas) (1.2.1)\n",
      "Requirement already satisfied: typing-inspect<1,>=0.4.0 in /home/dhanushb/.local/lib/python3.10/site-packages (from dataclasses-json<0.7,>=0.5.7->langchain-community->ragas) (0.9.0)\n",
      "Requirement already satisfied: marshmallow<4.0.0,>=3.18.0 in /home/dhanushb/.local/lib/python3.10/site-packages (from dataclasses-json<0.7,>=0.5.7->langchain-community->ragas) (3.21.2)\n",
      "Requirement already satisfied: httpcore==1.* in /home/dhanushb/.local/lib/python3.10/site-packages (from httpx<1,>=0.23.0->openai>1->ragas) (1.0.5)\n",
      "Requirement already satisfied: h11<0.15,>=0.13 in /home/dhanushb/.local/lib/python3.10/site-packages (from httpcore==1.*->httpx<1,>=0.23.0->openai>1->ragas) (0.14.0)\n",
      "Requirement already satisfied: jsonpointer>=1.9 in /home/dhanushb/.local/lib/python3.10/site-packages (from jsonpatch<2.0,>=1.33->langchain-core->ragas) (2.4)\n",
      "Requirement already satisfied: orjson<4.0.0,>=3.9.14 in /home/dhanushb/.local/lib/python3.10/site-packages (from langsmith<0.2.0,>=0.1.17->langchain->ragas) (3.10.3)\n",
      "Requirement already satisfied: annotated-types>=0.4.0 in /home/dhanushb/.local/lib/python3.10/site-packages (from pydantic<3,>=1.9.0->openai>1->ragas) (0.7.0)\n",
      "Requirement already satisfied: pydantic-core==2.18.3 in /home/dhanushb/.local/lib/python3.10/site-packages (from pydantic<3,>=1.9.0->openai>1->ragas) (2.18.3)\n",
      "Requirement already satisfied: six>=1.5 in /usr/lib/python3/dist-packages (from python-dateutil>=2.8.2->pandas->datasets) (1.16.0)\n",
      "Requirement already satisfied: greenlet!=0.4.17 in /usr/lib/python3/dist-packages (from SQLAlchemy<3,>=1.4->langchain->ragas) (1.1.2)\n",
      "Requirement already satisfied: mypy-extensions>=0.3.0 in /home/dhanushb/.local/lib/python3.10/site-packages (from typing-inspect<1,>=0.4.0->dataclasses-json<0.7,>=0.5.7->langchain-community->ragas) (1.0.0)\n",
      "Installing collected packages: appdirs, regex, pysbd, tiktoken, openai, langsmith, langchain-core, langchain-openai, ragas\n",
      "  Attempting uninstall: langsmith\n",
      "    Found existing installation: langsmith 0.1.63\n",
      "    Uninstalling langsmith-0.1.63:\n",
      "      Successfully uninstalled langsmith-0.1.63\n",
      "  Attempting uninstall: langchain-core\n",
      "    Found existing installation: langchain-core 0.2.1\n",
      "    Uninstalling langchain-core-0.2.1:\n",
      "      Successfully uninstalled langchain-core-0.2.1\n",
      "Successfully installed appdirs-1.4.4 langchain-core-0.2.3 langchain-openai-0.1.8 langsmith-0.1.69 openai-1.31.0 pysbd-0.3.4 ragas-0.1.9 regex-2024.5.15 tiktoken-0.7.0\n",
      "Note: you may need to restart the kernel to use updated packages.\n"
     ]
    }
   ],
   "source": [
    "%pip install datasets ragas"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "from dotenv import load_dotenv\n",
    "\n",
    "load_dotenv()\n",
    "OPENAI_API_KEY = os.getenv(\"OPENAI_API_KEY\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_openai import ChatOpenAI, OpenAIEmbeddings\n",
    "\n",
    "llm = ChatOpenAI(model = \"gpt-4o\", temperature = 0)\n",
    "embeddings = OpenAIEmbeddings()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "af743c1f018948788bbea3c2b12c64d5",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Evaluating:   0%|          | 0/1072 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "The LLM did not return a valid classification.\n",
      "The LLM did not return a valid classification.\n",
      "No statements were generated from the answer.\n",
      "No statements were generated from the answer.\n",
      "The LLM did not return a valid classification.\n",
      "The LLM did not return a valid classification.\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>question</th>\n",
       "      <th>answer</th>\n",
       "      <th>contexts</th>\n",
       "      <th>ground_truth</th>\n",
       "      <th>context_entity_recall</th>\n",
       "      <th>context_precision</th>\n",
       "      <th>context_recall</th>\n",
       "      <th>faithfulness</th>\n",
       "      <th>answer_relevancy</th>\n",
       "      <th>answer_similarity</th>\n",
       "      <th>answer_correctness</th>\n",
       "      <th>harmfulness</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>As part of my liver transplant, I take tacroli...</td>\n",
       "      <td>Based on your test results, if you are an ext...</td>\n",
       "      <td>[['recipients. Pharmacogenet Genomics 2008;18:...</td>\n",
       "      <td>For a CYP3A5 extensive metabolizer. Increase s...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.833333</td>\n",
       "      <td>0.885769</td>\n",
       "      <td>0.917294</td>\n",
       "      <td>0.460093</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>I'm Indian, and my family has a history of epi...</td>\n",
       "      <td>The genetic variant HLA-B*15:02 that you have...</td>\n",
       "      <td>[['{\"citations\": [{\"id\": 15071835, \"title\": \"R...</td>\n",
       "      <td>As per CPIC HLA-B*15:02 might be observed in 2...</td>\n",
       "      <td>0.166667</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.214286</td>\n",
       "      <td>0.832249</td>\n",
       "      <td>0.868482</td>\n",
       "      <td>0.341961</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Allopurinol is what I take for gout. For my se...</td>\n",
       "      <td>Answer: Phenytoin and allopurinol are two dis...</td>\n",
       "      <td>[['that a stronger inhibition of the uric acid...</td>\n",
       "      <td>There can be moderate interaction while consid...</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.076923</td>\n",
       "      <td>0.899576</td>\n",
       "      <td>0.867515</td>\n",
       "      <td>0.295826</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Is it true that while taking clopidogrel, I sh...</td>\n",
       "      <td>While taking clopidogrel, it is generally rec...</td>\n",
       "      <td>[['Drug: clopidogrel\\nGene1: CYP2C19\\nPhenotyp...</td>\n",
       "      <td>Indeed, you should refrain from drinking grape...</td>\n",
       "      <td>0.333333</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.263158</td>\n",
       "      <td>0.865722</td>\n",
       "      <td>0.918113</td>\n",
       "      <td>0.417028</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Dizziness is one of the adverse reactions that...</td>\n",
       "      <td>Based on the literature provided, there is ev...</td>\n",
       "      <td>[['1. \\nGanoci L et al. ABCB1, ABCG2 and CYP2D...</td>\n",
       "      <td>Dizziness drawiness,extreme thirst,fast, shall...</td>\n",
       "      <td>0.050000</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.400000</td>\n",
       "      <td>0.838969</td>\n",
       "      <td>0.867355</td>\n",
       "      <td>0.216839</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>129</th>\n",
       "      <td>My patient has CYP2D6 poor metabolism and does...</td>\n",
       "      <td>Based on the provided data, there are no spec...</td>\n",
       "      <td>[[\"Drug: sertraline\\nGene1: CYP2C19\\nPhenotype...</td>\n",
       "      <td>CPIC guideline for ondansetron and CYP2D6 has ...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.333333</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.804836</td>\n",
       "      <td>0.201209</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>130</th>\n",
       "      <td>What are side effects associated wtih DPYD poo...</td>\n",
       "      <td>The HLAB system is not directly involved in p...</td>\n",
       "      <td>[['Drug: lornoxicam\\nGene1: CYP2C9\\nPhenotype1...</td>\n",
       "      <td>5-FU has many adverse drug effects when used s...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.550000</td>\n",
       "      <td>0.804887</td>\n",
       "      <td>0.745304</td>\n",
       "      <td>0.186350</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>131</th>\n",
       "      <td>What are the pharmacogenomic panel advised to ...</td>\n",
       "      <td>The given text suggests that for a patient wi...</td>\n",
       "      <td>[['{\"citations\": [{\"id\": 15143242, \"title\": \"C...</td>\n",
       "      <td>G6PD, CYP2D6, UGT1A1</td>\n",
       "      <td>0.333333</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.333333</td>\n",
       "      <td>0.625000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.789297</td>\n",
       "      <td>0.197324</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>132</th>\n",
       "      <td>I have a 7 year old patient with HLA-B1502 pos...</td>\n",
       "      <td>The side effects associated with DPD (dihydro...</td>\n",
       "      <td>[['9\\n. \\nKristensen MH et al. Variants in the...</td>\n",
       "      <td>Sodium Valproate</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.900000</td>\n",
       "      <td>0.755927</td>\n",
       "      <td>0.770635</td>\n",
       "      <td>0.192643</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>133</th>\n",
       "      <td>What are the adverse outcomes associated with ...</td>\n",
       "      <td>To provide an appropriate pharmacogenomic (PG...</td>\n",
       "      <td>[[\"Drug: omeprazole\\nGene1: CYP2C19\\nPhenotype...</td>\n",
       "      <td>Patients with the rs1801133 AA genotype and Ar...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.116279</td>\n",
       "      <td>0.800904</td>\n",
       "      <td>0.783442</td>\n",
       "      <td>0.195867</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>134 rows × 12 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                              question  \\\n",
       "0    As part of my liver transplant, I take tacroli...   \n",
       "1    I'm Indian, and my family has a history of epi...   \n",
       "2    Allopurinol is what I take for gout. For my se...   \n",
       "3    Is it true that while taking clopidogrel, I sh...   \n",
       "4    Dizziness is one of the adverse reactions that...   \n",
       "..                                                 ...   \n",
       "129  My patient has CYP2D6 poor metabolism and does...   \n",
       "130  What are side effects associated wtih DPYD poo...   \n",
       "131  What are the pharmacogenomic panel advised to ...   \n",
       "132  I have a 7 year old patient with HLA-B1502 pos...   \n",
       "133  What are the adverse outcomes associated with ...   \n",
       "\n",
       "                                                answer  \\\n",
       "0     Based on your test results, if you are an ext...   \n",
       "1     The genetic variant HLA-B*15:02 that you have...   \n",
       "2     Answer: Phenytoin and allopurinol are two dis...   \n",
       "3     While taking clopidogrel, it is generally rec...   \n",
       "4     Based on the literature provided, there is ev...   \n",
       "..                                                 ...   \n",
       "129   Based on the provided data, there are no spec...   \n",
       "130   The HLAB system is not directly involved in p...   \n",
       "131   The given text suggests that for a patient wi...   \n",
       "132   The side effects associated with DPD (dihydro...   \n",
       "133   To provide an appropriate pharmacogenomic (PG...   \n",
       "\n",
       "                                              contexts  \\\n",
       "0    [['recipients. Pharmacogenet Genomics 2008;18:...   \n",
       "1    [['{\"citations\": [{\"id\": 15071835, \"title\": \"R...   \n",
       "2    [['that a stronger inhibition of the uric acid...   \n",
       "3    [['Drug: clopidogrel\\nGene1: CYP2C19\\nPhenotyp...   \n",
       "4    [['1. \\nGanoci L et al. ABCB1, ABCG2 and CYP2D...   \n",
       "..                                                 ...   \n",
       "129  [[\"Drug: sertraline\\nGene1: CYP2C19\\nPhenotype...   \n",
       "130  [['Drug: lornoxicam\\nGene1: CYP2C9\\nPhenotype1...   \n",
       "131  [['{\"citations\": [{\"id\": 15143242, \"title\": \"C...   \n",
       "132  [['9\\n. \\nKristensen MH et al. Variants in the...   \n",
       "133  [[\"Drug: omeprazole\\nGene1: CYP2C19\\nPhenotype...   \n",
       "\n",
       "                                          ground_truth  context_entity_recall  \\\n",
       "0    For a CYP3A5 extensive metabolizer. Increase s...               0.000000   \n",
       "1    As per CPIC HLA-B*15:02 might be observed in 2...               0.166667   \n",
       "2    There can be moderate interaction while consid...               0.500000   \n",
       "3    Indeed, you should refrain from drinking grape...               0.333333   \n",
       "4    Dizziness drawiness,extreme thirst,fast, shall...               0.050000   \n",
       "..                                                 ...                    ...   \n",
       "129  CPIC guideline for ondansetron and CYP2D6 has ...               0.000000   \n",
       "130  5-FU has many adverse drug effects when used s...               0.000000   \n",
       "131                               G6PD, CYP2D6, UGT1A1               0.333333   \n",
       "132                                   Sodium Valproate               0.000000   \n",
       "133  Patients with the rs1801133 AA genotype and Ar...               0.000000   \n",
       "\n",
       "     context_precision  context_recall  faithfulness  answer_relevancy  \\\n",
       "0                  1.0        1.000000      0.833333          0.885769   \n",
       "1                  1.0        0.500000      0.214286          0.832249   \n",
       "2                  1.0        0.000000      0.076923          0.899576   \n",
       "3                  0.0        0.000000      0.263158          0.865722   \n",
       "4                  1.0        0.500000      0.400000          0.838969   \n",
       "..                 ...             ...           ...               ...   \n",
       "129                0.0        0.000000      0.333333          0.000000   \n",
       "130                0.0        0.000000      0.550000          0.804887   \n",
       "131                0.0        0.333333      0.625000          0.000000   \n",
       "132                0.0        0.000000      0.900000          0.755927   \n",
       "133                0.0        0.000000      0.116279          0.800904   \n",
       "\n",
       "     answer_similarity  answer_correctness  harmfulness  \n",
       "0             0.917294            0.460093            0  \n",
       "1             0.868482            0.341961            0  \n",
       "2             0.867515            0.295826            0  \n",
       "3             0.918113            0.417028            0  \n",
       "4             0.867355            0.216839            0  \n",
       "..                 ...                 ...          ...  \n",
       "129           0.804836            0.201209            1  \n",
       "130           0.745304            0.186350            0  \n",
       "131           0.789297            0.197324            0  \n",
       "132           0.770635            0.192643            0  \n",
       "133           0.783442            0.195867            0  \n",
       "\n",
       "[134 rows x 12 columns]"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from datasets import Dataset\n",
    "from ragas import evaluate\n",
    "from ragas.metrics.critique import harmfulness\n",
    "from ragas.metrics import (\n",
    "    faithfulness,\n",
    "    answer_relevancy,\n",
    "    context_recall,\n",
    "    context_precision,\n",
    "    context_entity_recall,\n",
    "    answer_similarity,\n",
    "    answer_correctness,\n",
    ")\n",
    "\n",
    "# To dict\n",
    "data = {\n",
    "    \"question\": list(map(str, quests[\"Questions\"].to_list())),\n",
    "    \"answer\": list(map(str, quests[\"mistral_resp\"].to_list())),\n",
    "    \"contexts\": [[str(context)] for context in quests[\"context\"].to_list()],\n",
    "    \"ground_truth\": list(map(str, quests[\"Expected_response\"].to_list()))\n",
    "}\n",
    "\n",
    "# Convert dict to dataset\n",
    "dataset = Dataset.from_dict(data)\n",
    "\n",
    "result = evaluate(\n",
    "    dataset = dataset, \n",
    "    metrics=[\n",
    "        context_entity_recall,\n",
    "        context_precision,\n",
    "        context_recall,\n",
    "        faithfulness,\n",
    "        answer_relevancy,\n",
    "        answer_similarity,\n",
    "        answer_correctness,\n",
    "        harmfulness\n",
    "    ],\n",
    "    llm = llm,\n",
    "    embeddings= embeddings\n",
    ")\n",
    "df = result.to_pandas()\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "df.to_csv(\"/home/dhanushb/Wellytics/RAG_data/results/mistral_eval.csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "79bf6d83350b4c9880598384c2eb6dbe",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Evaluating:   0%|          | 0/1072 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "The LLM did not return a valid classification.\n",
      "No statements were generated from the answer.\n",
      "The LLM did not return a valid classification.\n",
      "No statements were generated from the answer.\n",
      "The LLM did not return a valid classification.\n",
      "No statements were generated from the answer.\n",
      "No statements were generated from the answer.\n",
      "No statements were generated from the answer.\n",
      "The LLM did not return a valid classification.\n",
      "No statements were generated from the answer.\n",
      "No statements were generated from the answer.\n"
     ]
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[17], line 12\u001b[0m\n\u001b[1;32m      9\u001b[0m \u001b[38;5;66;03m# Convert dict to dataset\u001b[39;00m\n\u001b[1;32m     10\u001b[0m dataset \u001b[38;5;241m=\u001b[39m Dataset\u001b[38;5;241m.\u001b[39mfrom_dict(data)\n\u001b[0;32m---> 12\u001b[0m result \u001b[38;5;241m=\u001b[39m \u001b[43mevaluate\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m     13\u001b[0m \u001b[43m    \u001b[49m\u001b[43mdataset\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m \u001b[49m\u001b[43mdataset\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\n\u001b[1;32m     14\u001b[0m \u001b[43m    \u001b[49m\u001b[43mmetrics\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m[\u001b[49m\n\u001b[1;32m     15\u001b[0m \u001b[43m        \u001b[49m\u001b[43mcontext_entity_recall\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m     16\u001b[0m \u001b[43m        \u001b[49m\u001b[43mcontext_precision\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m     17\u001b[0m \u001b[43m        \u001b[49m\u001b[43mcontext_recall\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m     18\u001b[0m \u001b[43m        \u001b[49m\u001b[43mfaithfulness\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m     19\u001b[0m \u001b[43m        \u001b[49m\u001b[43manswer_relevancy\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m     20\u001b[0m \u001b[43m        \u001b[49m\u001b[43manswer_similarity\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m     21\u001b[0m \u001b[43m        \u001b[49m\u001b[43manswer_correctness\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m     22\u001b[0m \u001b[43m        \u001b[49m\u001b[43mharmfulness\u001b[49m\n\u001b[1;32m     23\u001b[0m \u001b[43m    \u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m     24\u001b[0m \u001b[43m    \u001b[49m\u001b[43mllm\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m \u001b[49m\u001b[43mllm\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m     25\u001b[0m \u001b[43m    \u001b[49m\u001b[43membeddings\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m \u001b[49m\u001b[43membeddings\u001b[49m\n\u001b[1;32m     26\u001b[0m \u001b[43m)\u001b[49m\n\u001b[1;32m     27\u001b[0m df \u001b[38;5;241m=\u001b[39m result\u001b[38;5;241m.\u001b[39mto_pandas()\n\u001b[1;32m     28\u001b[0m df\u001b[38;5;241m.\u001b[39mto_csv(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m/home/dhanushb/Wellytics/RAG_data/results/gemma_eval.csv\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n",
      "File \u001b[0;32m~/.local/lib/python3.10/site-packages/ragas/evaluation.py:230\u001b[0m, in \u001b[0;36mevaluate\u001b[0;34m(dataset, metrics, llm, embeddings, callbacks, in_ci, is_async, run_config, raise_exceptions, column_map)\u001b[0m\n\u001b[1;32m    227\u001b[0m scores \u001b[38;5;241m=\u001b[39m []\n\u001b[1;32m    228\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m    229\u001b[0m     \u001b[38;5;66;03m# get the results\u001b[39;00m\n\u001b[0;32m--> 230\u001b[0m     results \u001b[38;5;241m=\u001b[39m \u001b[43mexecutor\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mresults\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    231\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m results \u001b[38;5;241m==\u001b[39m []:\n\u001b[1;32m    232\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m ExceptionInRunner()\n",
      "File \u001b[0;32m~/.local/lib/python3.10/site-packages/ragas/executor.py:131\u001b[0m, in \u001b[0;36mExecutor.results\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    129\u001b[0m executor_job\u001b[38;5;241m.\u001b[39mstart()\n\u001b[1;32m    130\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m--> 131\u001b[0m     \u001b[43mexecutor_job\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mjoin\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    132\u001b[0m \u001b[38;5;28;01mfinally\u001b[39;00m:\n\u001b[1;32m    133\u001b[0m     \u001b[38;5;241m.\u001b[39m\u001b[38;5;241m.\u001b[39m\u001b[38;5;241m.\u001b[39m\n",
      "File \u001b[0;32m/usr/lib/python3.10/threading.py:1096\u001b[0m, in \u001b[0;36mThread.join\u001b[0;34m(self, timeout)\u001b[0m\n\u001b[1;32m   1093\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mRuntimeError\u001b[39;00m(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mcannot join current thread\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[1;32m   1095\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m timeout \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[0;32m-> 1096\u001b[0m     \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_wait_for_tstate_lock\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m   1097\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m   1098\u001b[0m     \u001b[38;5;66;03m# the behavior of a negative timeout isn't documented, but\u001b[39;00m\n\u001b[1;32m   1099\u001b[0m     \u001b[38;5;66;03m# historically .join(timeout=x) for x<0 has acted as if timeout=0\u001b[39;00m\n\u001b[1;32m   1100\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_wait_for_tstate_lock(timeout\u001b[38;5;241m=\u001b[39m\u001b[38;5;28mmax\u001b[39m(timeout, \u001b[38;5;241m0\u001b[39m))\n",
      "File \u001b[0;32m/usr/lib/python3.10/threading.py:1116\u001b[0m, in \u001b[0;36mThread._wait_for_tstate_lock\u001b[0;34m(self, block, timeout)\u001b[0m\n\u001b[1;32m   1113\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m\n\u001b[1;32m   1115\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m-> 1116\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[43mlock\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43macquire\u001b[49m\u001b[43m(\u001b[49m\u001b[43mblock\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m)\u001b[49m:\n\u001b[1;32m   1117\u001b[0m         lock\u001b[38;5;241m.\u001b[39mrelease()\n\u001b[1;32m   1118\u001b[0m         \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_stop()\n",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m: "
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Exception ignored in: Exception ignored in: <generator object tqdm.__iter__ at 0x73354c218740>\n",
      "Traceback (most recent call last):\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/tqdm/std.py\", line 1196, in __iter__\n",
      "    self.close()\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/tqdm/notebook.py\", line 279, in close\n",
      "    self.disp(bar_style='danger', check_delay=False)\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/tqdm/notebook.py\", line 157, in display\n",
      "    pbar.value = self.n\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/traitlets/traitlets.py\", line 716, in __set__\n",
      "    self.set(obj, value)\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/traitlets/traitlets.py\", line 706, in set\n",
      "    obj._notify_trait(self.name, old_value, new_value)\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/traitlets/traitlets.py\", line 1513, in _notify_trait\n",
      "    self.notify_change(\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ipywidgets/widgets/widget.py\", line 700, in notify_change\n",
      "    self.send_state(key=name)\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ipywidgets/widgets/widget.py\", line 586, in send_state\n",
      "    self._send(msg, buffers=buffers)\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ipywidgets/widgets/widget.py\", line 825, in _send\n",
      "    self.comm.send(data=msg, buffers=buffers)\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/comm/base_comm.py\", line 147, in send\n",
      "    self.publish_msg(\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ipykernel/comm/comm.py\", line 37, in publish_msg\n",
      "    self.kernel.session.send(\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/jupyter_client/session.py\", line 863, in send\n",
      "    stream.send_multipart(to_send, copy=copy)\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ipykernel/iostream.py\", line 346, in send_multipart\n",
      "    return self.io_thread.send_multipart(*args, **kwargs)\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ipykernel/iostream.py\", line 276, in send_multipart\n",
      "    self.schedule(lambda: self._really_send(*args, **kwargs))\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ipykernel/iostream.py\", line 267, in schedule\n",
      "    self._event_pipe.send(b\"\")\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/zmq/sugar/socket.py\", line 701, in send\n",
      "    return super().send(data, flags=flags, copy=copy, track=track)\n",
      "  File \"_zmq.py\", line 1073, in zmq.backend.cython._zmq.Socket.send\n",
      "  File \"_zmq.py\", line 1115, in zmq.backend.cython._zmq.Socket.send\n",
      "  File \"_zmq.py\", line 1190, in zmq.backend.cython._zmq._check_closed\n",
      "zmq.error.ZMQError: Socket operation on non-socket\n",
      "Exception ignored in sys.unraisablehook: <built-in function unraisablehook>\n",
      "Traceback (most recent call last):\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ipykernel/iostream.py\", line 604, in flush\n",
      "    self.pub_thread.schedule(self._flush)\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ipykernel/iostream.py\", line 267, in schedule\n",
      "    self._event_pipe.send(b\"\")\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/zmq/sugar/socket.py\", line 701, in send\n",
      "    return super().send(data, flags=flags, copy=copy, track=track)\n",
      "  File \"_zmq.py\", line 1073, in zmq.backend.cython._zmq.Socket.send\n",
      "  File \"_zmq.py\", line 1115, in zmq.backend.cython._zmq.Socket.send\n",
      "  File \"_zmq.py\", line 1190, in zmq.backend.cython._zmq._check_closed\n",
      "zmq.error.ZMQError: Socket operation on non-socket\n",
      "Exception ignored in sys.unraisablehook: <built-in function unraisablehook>\n",
      "Traceback (most recent call last):\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ipykernel/iostream.py\", line 694, in write\n",
      "    self._schedule_flush()\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ipykernel/iostream.py\", line 590, in _schedule_flush\n",
      "    self.pub_thread.schedule(_schedule_in_thread)\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ipykernel/iostream.py\", line 267, in schedule\n",
      "    self._event_pipe.send(b\"\")\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/zmq/sugar/socket.py\", line 701, in send\n",
      "    return super().send(data, flags=flags, copy=copy, track=track)\n",
      "  File \"_zmq.py\", line 1073, in zmq.backend.cython._zmq.Socket.send\n",
      "  File \"_zmq.py\", line 1115, in zmq.backend.cython._zmq.Socket.send\n",
      "  File \"_zmq.py\", line 1190, in zmq.backend.cython._zmq._check_closed\n",
      "zmq.error.ZMQError: Socket operation on non-socket\n",
      "Exception in thread Thread-87:\n",
      "Traceback (most recent call last):\n",
      "  File \"/usr/lib/python3.10/threading.py\", line 1016, in _bootstrap_inner\n",
      "    self.run()\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ragas/executor.py\", line 95, in run\n",
      "    results = self.loop.run_until_complete(self._aresults())\n",
      "  File \"/usr/lib/python3.10/asyncio/base_events.py\", line 649, in run_until_complete\n",
      "    return future.result()\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ragas/executor.py\", line 83, in _aresults\n",
      "    raise e\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ragas/executor.py\", line 78, in _aresults\n",
      "    r = await future\n",
      "  File \"/usr/lib/python3.10/asyncio/tasks.py\", line 571, in _wait_for_one\n",
      "    return f.result()  # May raise f.exception().\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ragas/executor.py\", line 37, in sema_coro\n",
      "    return await coro\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ragas/executor.py\", line 111, in wrapped_callable_async\n",
      "    return counter, await callable(*args, **kwargs)\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ragas/metrics/base.py\", line 125, in ascore\n",
      "    raise e\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ragas/metrics/base.py\", line 121, in ascore\n",
      "    score = await self._ascore(row=row, callbacks=group_cm, is_async=is_async)\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ragas/metrics/_context_entities_recall.py\", line 183, in _ascore\n",
      "    contexts = await self.get_entities(\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ragas/metrics/_context_entities_recall.py\", line 154, in get_entities\n",
      "    assert self.llm is not None, \"LLM is not initialized\"\n",
      "AssertionError: LLM is not initialized\n",
      "Exception in threading.excepthook:\n",
      "Exception ignored in thread started by: <bound method Thread._bootstrap of <Runner(Thread-87, stopped 126669681587776)>>\n",
      "Traceback (most recent call last):\n",
      "  File \"/usr/lib/python3.10/threading.py\", line 973, in _bootstrap\n",
      "    self._bootstrap_inner()\n",
      "  File \"/usr/lib/python3.10/threading.py\", line 1018, in _bootstrap_inner\n",
      "    self._invoke_excepthook(self)\n",
      "  File \"/usr/lib/python3.10/threading.py\", line 1336, in invoke_excepthook\n",
      "    local_print(\"Exception in threading.excepthook:\",\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ipykernel/iostream.py\", line 604, in flush\n",
      "    self.pub_thread.schedule(self._flush)\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ipykernel/iostream.py\", line 267, in schedule\n",
      "    self._event_pipe.send(b\"\")\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/zmq/sugar/socket.py\", line 701, in send\n",
      "    return super().send(data, flags=flags, copy=copy, track=track)\n",
      "  File \"_zmq.py\", line 1073, in zmq.backend.cython._zmq.Socket.send\n",
      "  File \"_zmq.py\", line 1115, in zmq.backend.cython._zmq.Socket.send\n",
      "  File \"_zmq.py\", line 1190, in zmq.backend.cython._zmq._check_closed\n",
      "zmq.error.ZMQError: Socket operation on non-socket\n",
      "Exception ignored in sys.unraisablehook: <built-in function unraisablehook>\n",
      "Traceback (most recent call last):\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ipykernel/iostream.py\", line 604, in flush\n",
      "    self.pub_thread.schedule(self._flush)\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/ipykernel/iostream.py\", line 267, in schedule\n",
      "    self._event_pipe.send(b\"\")\n",
      "  File \"/home/dhanushb/.local/lib/python3.10/site-packages/zmq/sugar/socket.py\", line 701, in send\n",
      "    return super().send(data, flags=flags, copy=copy, track=track)\n",
      "  File \"_zmq.py\", line 1073, in zmq.backend.cython._zmq.Socket.send\n",
      "  File \"_zmq.py\", line 1115, in zmq.backend.cython._zmq.Socket.send\n",
      "  File \"_zmq.py\", line 1190, in zmq.backend.cython._zmq._check_closed\n",
      "zmq.error.ZMQError: Socket operation on non-socket\n"
     ]
    }
   ],
   "source": [
    "# To dict\n",
    "data = {\n",
    "    \"question\": list(map(str, quests[\"Questions\"].to_list())),\n",
    "    \"answer\": list(map(str, quests[\"gemma_resp\"].to_list())),\n",
    "    \"contexts\": [[str(context)] for context in quests[\"context\"].to_list()],\n",
    "    \"ground_truth\": list(map(str, quests[\"Expected_response\"].to_list()))\n",
    "}\n",
    "\n",
    "# Convert dict to dataset\n",
    "dataset = Dataset.from_dict(data)\n",
    "\n",
    "result = evaluate(\n",
    "    dataset = dataset, \n",
    "    metrics=[\n",
    "        context_entity_recall,\n",
    "        context_precision,\n",
    "        context_recall,\n",
    "        faithfulness,\n",
    "        answer_relevancy,\n",
    "        answer_similarity,\n",
    "        answer_correctness,\n",
    "        harmfulness\n",
    "    ],\n",
    "    llm = llm,\n",
    "    embeddings= embeddings\n",
    ")\n",
    "df = result.to_pandas()\n",
    "df.to_csv(\"/home/dhanushb/Wellytics/RAG_data/results/gemma_eval.csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>question</th>\n",
       "      <th>answer</th>\n",
       "      <th>contexts</th>\n",
       "      <th>ground_truth</th>\n",
       "      <th>context_entity_recall</th>\n",
       "      <th>context_precision</th>\n",
       "      <th>context_recall</th>\n",
       "      <th>faithfulness</th>\n",
       "      <th>answer_relevancy</th>\n",
       "      <th>answer_similarity</th>\n",
       "      <th>answer_correctness</th>\n",
       "      <th>harmfulness</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>As part of my liver transplant, I take tacroli...</td>\n",
       "      <td>Based on your test results, if you are an ext...</td>\n",
       "      <td>[['recipients. Pharmacogenet Genomics 2008;18:...</td>\n",
       "      <td>For a CYP3A5 extensive metabolizer. Increase s...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.833333</td>\n",
       "      <td>0.885769</td>\n",
       "      <td>0.917294</td>\n",
       "      <td>0.460093</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>I'm Indian, and my family has a history of epi...</td>\n",
       "      <td>The genetic variant HLA-B*15:02 that you have...</td>\n",
       "      <td>[['{\"citations\": [{\"id\": 15071835, \"title\": \"R...</td>\n",
       "      <td>As per CPIC HLA-B*15:02 might be observed in 2...</td>\n",
       "      <td>0.166667</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.214286</td>\n",
       "      <td>0.832249</td>\n",
       "      <td>0.868482</td>\n",
       "      <td>0.341961</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Allopurinol is what I take for gout. For my se...</td>\n",
       "      <td>Answer: Phenytoin and allopurinol are two dis...</td>\n",
       "      <td>[['that a stronger inhibition of the uric acid...</td>\n",
       "      <td>There can be moderate interaction while consid...</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.076923</td>\n",
       "      <td>0.899576</td>\n",
       "      <td>0.867515</td>\n",
       "      <td>0.295826</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Is it true that while taking clopidogrel, I sh...</td>\n",
       "      <td>While taking clopidogrel, it is generally rec...</td>\n",
       "      <td>[['Drug: clopidogrel\\nGene1: CYP2C19\\nPhenotyp...</td>\n",
       "      <td>Indeed, you should refrain from drinking grape...</td>\n",
       "      <td>0.333333</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.263158</td>\n",
       "      <td>0.865722</td>\n",
       "      <td>0.918113</td>\n",
       "      <td>0.417028</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Dizziness is one of the adverse reactions that...</td>\n",
       "      <td>Based on the literature provided, there is ev...</td>\n",
       "      <td>[['1. \\nGanoci L et al. ABCB1, ABCG2 and CYP2D...</td>\n",
       "      <td>Dizziness drawiness,extreme thirst,fast, shall...</td>\n",
       "      <td>0.050000</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.400000</td>\n",
       "      <td>0.838969</td>\n",
       "      <td>0.867355</td>\n",
       "      <td>0.216839</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>129</th>\n",
       "      <td>My patient has CYP2D6 poor metabolism and does...</td>\n",
       "      <td>Based on the provided data, there are no spec...</td>\n",
       "      <td>[[\"Drug: sertraline\\nGene1: CYP2C19\\nPhenotype...</td>\n",
       "      <td>CPIC guideline for ondansetron and CYP2D6 has ...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.333333</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.804836</td>\n",
       "      <td>0.201209</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>130</th>\n",
       "      <td>What are side effects associated wtih DPYD poo...</td>\n",
       "      <td>The HLAB system is not directly involved in p...</td>\n",
       "      <td>[['Drug: lornoxicam\\nGene1: CYP2C9\\nPhenotype1...</td>\n",
       "      <td>5-FU has many adverse drug effects when used s...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.550000</td>\n",
       "      <td>0.804887</td>\n",
       "      <td>0.745304</td>\n",
       "      <td>0.186350</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>131</th>\n",
       "      <td>What are the pharmacogenomic panel advised to ...</td>\n",
       "      <td>The given text suggests that for a patient wi...</td>\n",
       "      <td>[['{\"citations\": [{\"id\": 15143242, \"title\": \"C...</td>\n",
       "      <td>G6PD, CYP2D6, UGT1A1</td>\n",
       "      <td>0.333333</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.333333</td>\n",
       "      <td>0.625000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.789297</td>\n",
       "      <td>0.197324</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>132</th>\n",
       "      <td>I have a 7 year old patient with HLA-B1502 pos...</td>\n",
       "      <td>The side effects associated with DPD (dihydro...</td>\n",
       "      <td>[['9\\n. \\nKristensen MH et al. Variants in the...</td>\n",
       "      <td>Sodium Valproate</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.900000</td>\n",
       "      <td>0.755927</td>\n",
       "      <td>0.770635</td>\n",
       "      <td>0.192643</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>133</th>\n",
       "      <td>What are the adverse outcomes associated with ...</td>\n",
       "      <td>To provide an appropriate pharmacogenomic (PG...</td>\n",
       "      <td>[[\"Drug: omeprazole\\nGene1: CYP2C19\\nPhenotype...</td>\n",
       "      <td>Patients with the rs1801133 AA genotype and Ar...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.116279</td>\n",
       "      <td>0.800904</td>\n",
       "      <td>0.783442</td>\n",
       "      <td>0.195867</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>134 rows × 12 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                              question  \\\n",
       "0    As part of my liver transplant, I take tacroli...   \n",
       "1    I'm Indian, and my family has a history of epi...   \n",
       "2    Allopurinol is what I take for gout. For my se...   \n",
       "3    Is it true that while taking clopidogrel, I sh...   \n",
       "4    Dizziness is one of the adverse reactions that...   \n",
       "..                                                 ...   \n",
       "129  My patient has CYP2D6 poor metabolism and does...   \n",
       "130  What are side effects associated wtih DPYD poo...   \n",
       "131  What are the pharmacogenomic panel advised to ...   \n",
       "132  I have a 7 year old patient with HLA-B1502 pos...   \n",
       "133  What are the adverse outcomes associated with ...   \n",
       "\n",
       "                                                answer  \\\n",
       "0     Based on your test results, if you are an ext...   \n",
       "1     The genetic variant HLA-B*15:02 that you have...   \n",
       "2     Answer: Phenytoin and allopurinol are two dis...   \n",
       "3     While taking clopidogrel, it is generally rec...   \n",
       "4     Based on the literature provided, there is ev...   \n",
       "..                                                 ...   \n",
       "129   Based on the provided data, there are no spec...   \n",
       "130   The HLAB system is not directly involved in p...   \n",
       "131   The given text suggests that for a patient wi...   \n",
       "132   The side effects associated with DPD (dihydro...   \n",
       "133   To provide an appropriate pharmacogenomic (PG...   \n",
       "\n",
       "                                              contexts  \\\n",
       "0    [['recipients. Pharmacogenet Genomics 2008;18:...   \n",
       "1    [['{\"citations\": [{\"id\": 15071835, \"title\": \"R...   \n",
       "2    [['that a stronger inhibition of the uric acid...   \n",
       "3    [['Drug: clopidogrel\\nGene1: CYP2C19\\nPhenotyp...   \n",
       "4    [['1. \\nGanoci L et al. ABCB1, ABCG2 and CYP2D...   \n",
       "..                                                 ...   \n",
       "129  [[\"Drug: sertraline\\nGene1: CYP2C19\\nPhenotype...   \n",
       "130  [['Drug: lornoxicam\\nGene1: CYP2C9\\nPhenotype1...   \n",
       "131  [['{\"citations\": [{\"id\": 15143242, \"title\": \"C...   \n",
       "132  [['9\\n. \\nKristensen MH et al. Variants in the...   \n",
       "133  [[\"Drug: omeprazole\\nGene1: CYP2C19\\nPhenotype...   \n",
       "\n",
       "                                          ground_truth  context_entity_recall  \\\n",
       "0    For a CYP3A5 extensive metabolizer. Increase s...               0.000000   \n",
       "1    As per CPIC HLA-B*15:02 might be observed in 2...               0.166667   \n",
       "2    There can be moderate interaction while consid...               0.500000   \n",
       "3    Indeed, you should refrain from drinking grape...               0.333333   \n",
       "4    Dizziness drawiness,extreme thirst,fast, shall...               0.050000   \n",
       "..                                                 ...                    ...   \n",
       "129  CPIC guideline for ondansetron and CYP2D6 has ...               0.000000   \n",
       "130  5-FU has many adverse drug effects when used s...               0.000000   \n",
       "131                               G6PD, CYP2D6, UGT1A1               0.333333   \n",
       "132                                   Sodium Valproate               0.000000   \n",
       "133  Patients with the rs1801133 AA genotype and Ar...               0.000000   \n",
       "\n",
       "     context_precision  context_recall  faithfulness  answer_relevancy  \\\n",
       "0                  1.0        1.000000      0.833333          0.885769   \n",
       "1                  1.0        0.500000      0.214286          0.832249   \n",
       "2                  1.0        0.000000      0.076923          0.899576   \n",
       "3                  0.0        0.000000      0.263158          0.865722   \n",
       "4                  1.0        0.500000      0.400000          0.838969   \n",
       "..                 ...             ...           ...               ...   \n",
       "129                0.0        0.000000      0.333333          0.000000   \n",
       "130                0.0        0.000000      0.550000          0.804887   \n",
       "131                0.0        0.333333      0.625000          0.000000   \n",
       "132                0.0        0.000000      0.900000          0.755927   \n",
       "133                0.0        0.000000      0.116279          0.800904   \n",
       "\n",
       "     answer_similarity  answer_correctness  harmfulness  \n",
       "0             0.917294            0.460093            0  \n",
       "1             0.868482            0.341961            0  \n",
       "2             0.867515            0.295826            0  \n",
       "3             0.918113            0.417028            0  \n",
       "4             0.867355            0.216839            0  \n",
       "..                 ...                 ...          ...  \n",
       "129           0.804836            0.201209            1  \n",
       "130           0.745304            0.186350            0  \n",
       "131           0.789297            0.197324            0  \n",
       "132           0.770635            0.192643            0  \n",
       "133           0.783442            0.195867            0  \n",
       "\n",
       "[134 rows x 12 columns]"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "result.to_pandas()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['The provided text does not contain any information regarding the interpretation of pharmacogenetic test results or the implications of being a CYP3A5 extensive metabolizer. Therefore, I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding the impact of HLA-B*15:02 variation on the use of anticonvulsants in Indian patients. Therefore, I am unable to answer your question from the given context.',\n",
       " 'The provided text does not contain any information regarding the potential interaction between allopurinol and phenytoin, so I am unable to answer your question from the given context.',\n",
       " 'The provided text does not contain information regarding the interaction between clopidogrel and grapefruit or grapefruit juice, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding the correlation between genetic testing and dizziness as an adverse reaction to risperidone. Therefore, I am unable to answer this question from the given context.',\n",
       " 'nan',\n",
       " 'The provided text does not contain any information regarding the impact of weight or race on statin medications, so I am unable to answer your question from the given context.',\n",
       " \"**Based on the provided information, the chances of successfully resolving the muscle discomfort issue through medication adjustment are good.**\\n\\n**SLCO1B1 gene variation can indeed contribute to statin-induced myopathy.**\\n\\n- The test results indicate decreased function of SLCO1B1, which affects the transport of simvastatin (a commonly prescribed statin) to the liver.\\n- This reduction in transport can lead to increased plasma concentrations of simvastatin, which can increase the risk of side effects.\\n\\n**Statins affected by SLCO1B1 variations:**\\n\\n- Simvastatin\\n- Torvastatin\\n\\n**Statins not affected by SLCO1B1 variations:**\\n\\n- Atorvastatin\\n- Rosuvastatin\\n- Pravastatin\\n- Fluvastatin\\n\\n**Recommendations for your situation:**\\n\\n- **Continue taking atorvastatin:** As your doctor has confirmed that atorvastatin is not affected by the SLCO1B1 gene variation, it is unlikely that changing the medication will resolve the muscle discomfort.\\n- **Consult your doctor again:** Discuss your symptoms and concerns with your doctor. They can assess your situation and provide specific recommendations for dosage adjustments or alternative medications.\\n\\n**Possible outcomes:**\\n\\n- **Reduced muscle discomfort:** Adjusting the dosage or switching to a different statin medication may effectively reduce or eliminate the muscle discomfort you experienced.\\n- **No significant change:** In some cases, adjusting the medication may not completely eliminate the risk of muscle side effects.\\n\\n**Note:**\\n\\n- It is important to follow your doctor's recommendations and continue monitoring your symptoms.\\n- Communicate any new muscle symptoms to your doctor promptly.\",\n",
       " '**CYP2C19 diplotype *3/*17 indicates that you are an \"intermediate metabolizer\" of CYP2C19.**\\n\\n**Implications for PPI cases:**\\n\\n* **Pantoprazole:** For pantoprazole, intermediate metabolizers might require slightly higher doses to achieve the desired therapeutic effect. Your doctor may recommend dose adjustments based on your clinical response and tolerance.\\n* **Omeprazole:** For omeprazole, intermediate metabolizers have increased metabolism, leading to reduced blood levels of the drug and potentially diminished therapeutic effect. Your doctor might recommend a higher dose or more frequent dosing to achieve therapeutic concentrations.\\n\\n**Recommendations for PPI cases with CYP2C19 intermediate metabolism:**\\n\\n* Consult your doctor to determine the appropriate dose adjustment for your specific condition.\\n* Monitor your response to treatment and report any persisting symptoms of dyspepsia.\\n* Consider alternative PPIs or other acid-reducing medications that are not primarily metabolized by CYP2C19 if necessary.',\n",
       " 'The provided text does not contain any information regarding the safety of citalopram during pregnancy or its potential effects on the fetus, so I am unable to answer this question from the given context. Please consult with a healthcare professional for reliable and accurate information regarding the use of medications during pregnancy.',\n",
       " 'The provided text does not contain any information regarding capecitabine or genetic tests related to it, so I am unable to answer this question from the given context.',\n",
       " '**Explanation:**\\n\\nThe provided text explains that people with **TPMT Poor Metabolizer and NUDT15 Intermediate Metabolizer** gene variants experience **increased risk of myelosuppression** (leucopenia) when receiving certain medications, including thioguanine.\\n\\n**Specifically:**\\n\\n* TPMT gene mutation affects the metabolism of thioguanine, leading to accumulation of an active metabolite that can suppress bone marrow function.\\n* NUDT15 gene mutation further affects the metabolism of thioguanine, resulting in prolonged retention of the active metabolite.\\n\\n**Therefore:**\\n\\n* Your doctor believes that increasing your thioguanine dosage would likely cause severe myelosuppression in your case.\\n* She has recommended a switch to a different drug that does not pose the same risk of myelosuppression.\\n\\n**Note:** The text does not provide specific information about the alternative drug recommended by your doctor.',\n",
       " 'The provided text does not contain any information regarding the relationship between DPYD gene variations and side effects from tegafur, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding NSAIDs or CYP2C9 testing recommendations, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding quetiapine-related symptoms or genetic testing recommendations, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding G6PD deficiency, nitrofurantoin, or medication effectiveness, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain information regarding the effectiveness of medications based on weight or race, so I am unable to answer the question regarding your situation. It is recommended to consult with a healthcare professional for personalized medical advice and treatment options.',\n",
       " 'The provided text does not contain any information regarding the effects of carbamazepine or its interaction with genetic variations, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain information regarding the side effects of flucytosine in relation to DPYD gene variations, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding the effects of CYP2C9 and VKORC1 polymorphisms on vision or limb weakness in patients using acenocoumarol, so I am unable to answer this question from the given context.',\n",
       " 'The provided text suggests that the **SLCO1B1 gene test** can influence statin prescribing decisions\", \"',\n",
       " 'The provided text does not contain any information regarding pharmacogenomic tests or their ability to identify variations in the VKORC1, CYP2C19, and CYP2C9 genes or their impact on cardiovascular medications. Therefore, I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain information regarding pharmacogenomic or pharmacogenetic testing or its relevance to immuno suppressants prescription, so I am unable to answer this question from the given context.',\n",
       " 'The provided text discusses the impact of genetic variations on the response to two medications: efavirenz and fluvastatin. However, it does not contain any information regarding how genes affect the response to antiviral medications. Therefore, I am unable to answer your question from the given context.',\n",
       " 'The provided text does not contain any information regarding statins or their pharmacogenomic testing, so I am unable to answer this question from the given context.',\n",
       " '**CYP2D6 gene variations:**\\n\\n* Reduce the conversion of tramadol to a metabolite with a higher activity.\\n* Can result in reduced analgesia.\\n\\n\\n**CYP2C9 gene variations:**\\n\\n* May lead to a decrease in the required maintenance dose of acenocoumarol for blood clotting.\\n* However, there is insufficient evidence that this causes problems when therapy is initiated as usual.\\n\\n\\n**Impact on Analgesic Processing:**\\n\\n- **CYP2D6 gene variations:**\\n    - Can affect the effectiveness of tramadol, leading to decreased effectiveness.\\n\\nIn summary, variations in the metabolism of tramadol in patients with CYP2C11 gene polymorphisms.',\n",
       " 'The provided text does not contain any information regarding the effects of the HLA-B*15:02 gene variation on response to thiopurine medications, so I am unable to answer this question from the given context.',\n",
       " 'The provided text suggests that mutations in the CYP2D6 gene can impact the recommended dosage for propafenone. \\n\\n**Mutations in the CYP2D6 gene can:**\\n\\n- Increase the sum of plasma concentrations of propafenone and its active metabolite, 5-hydroxypropafenone, leading to a higher risk of side effects.\\n- Require a dose reduction to 30% of the standard dose. \\n\\n**Therefore, if you have mutations in the CYP2D6 gene, it is important to consult with your healthcare provider to determine the appropriate dosage of propafenone for your individual situation.**',\n",
       " '**Decreased function in the CYP2D6 gene can impact the type and dose of antipsychotics you can take.**\\n\\n**CYP2D6 enzyme plays a role in metabolizing certain antipsychotics:**\\n\\n- Haloperidol\\n- Aripiprazole\\n- Risperidone\\n- Paliperidone\\n- Zuclopenthixol\\n\\n**If you have decreased CYP2D6 function:**\\n\\n- Your doctor will likely recommend avoiding or cautiously using these antipsychotics, as they may accumulate in your body due to impaired metabolism.\\n- The dose of these medications will need to be carefully adjusted to minimize the risk of side effects and toxicity.\\n- Close monitoring of your blood levels and symptoms is essential to ensure appropriate dosing.\\n\\n**Your healthcare provider will work with you to determine the best treatment options based on your individual genetic profile and medical history.**',\n",
       " 'The provided text does not contain any information regarding the significance of an *1/*17 CYP2C19 diplotype for anti-depressants, so I am unable to answer this question from the given context.',\n",
       " 'Based on the provided information, your doctor has identified two genetic variations that may impact your response to metoprolol, a medication commonly used for heart disease.\\n\\n* **SLCO1B1 Poor Function:** This variation affects a transporter protein responsible for moving metoprolol into the liver. Reduced function can lead to lower clearance of the drug, potentially increasing plasma concentrations and side effects.',\n",
       " 'The provided text does not contain any information regarding the effects of a CYP2D6 diplotype of *1/*2x2 on ondansetron, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding the impact of CYP2D6 Poor Metabolizer and DPYD Intermediate Metabolizer on anti-neoplastic substances, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain information regarding the connection between antifungal drugs and blurry vision, diarrhea, and vomiting, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding turmeric as a natural alternative to NSAIDS, so I am unable to answer this question from the given context.',\n",
       " \"The provided text does not contain any information regarding eliglustat, Gaucher's disease, or antiarrhythmic medications, so I am unable to answer this question from the given context.\",\n",
       " 'The provided text does not contain any information regarding traveling with SSRI antidepressants, so I am unable to answer this question from the given context.',\n",
       " 'Based on the provided information, it is recommended to consider an alternative antiaggregant that is not a',\n",
       " 'The provided text does not contain information regarding brand names for clopidogrel, so I am unable to answer this question from the given context.',\n",
       " 'The provided text suggests that your doctor is considering your UGT1A1 gene to determine your risk of experiencing side effects from Camptosar (irinotecan), a chemotherapy drug commonly used for colorectal cancer treatment.\\n\\n**UGT1A1 gene variations can impact the metabolism of Camptosar:**\\n\\n- UGT1A1 is an enzyme involved in the glucuronidation process of Camptosar, which helps eliminate the drug from the body.\\n- Variations in the UGT1A1 gene can affect the efficiency of this metabolism process, leading to potentially increased blood levels of Camptosar.\\n- High blood levels of Camptosar can increase the risk of side effects, such as neutropenia (low white blood cell count) and diarrhea.\\n\\n**Therefore, knowing your UGT1A1 gene status allows your doctor to:**\\n\\n- Assess your individual risk of Camptosar-related side effects.\\n- Tailor the dose or treatment regimen to minimize potential risks.\\n\\n**Action may be needed if you have specific UGT1A1 variations:**\\n\\n- The text does not provide specific details about the consequences of your particular UGT1A1 gene variation, so consult your doctor for more information.\\n- Depending on the variation, your doctor may recommend:\\n    - Adjusting the Camptosar dose.\\n    - Monitoring your blood levels of Camptosar and other relevant markers.\\n    - Considering alternative chemotherapy options with different metabolism pathways.',\n",
       " 'The provided text does not contain any information regarding the impact of CYP2C9 intermediate metabolism on Vivlodex',\n",
       " 'The provided text does not contain any information regarding safe medications for patients with CYPC2C9 *2/*3 diplotype, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding specific genetic combinations for drugs relevant to your medical conditions, so I am unable to provide an answer to your question from the given context.',\n",
       " 'The provided text does not contain any information regarding the inference related to the ACE rs1799752 insertion/deletion polymorphism, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding the significance of the rs1800559 TT status of the CACNA1S gene, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain information regarding the risk of myopathy associated with Lescol XL based on your specific CYP2C9 and SLCO1B1 genotypes. Therefore, I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding when to repeat pharmacogenomics testing, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding the effects of CYP2C19 variation on gastritis or ulcers, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding Celera or its dosage, so I am unable to answer your question.',\n",
       " 'The provided text does not contain any information regarding precautions for severe diabetics with high Hb1Ac levels taking Ramipril, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding pharmacogenomics testing for hyperuricemia caused by rasburnat in lymphoma patients, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding the suitability of sertraline for individuals with high blood pressure or their CYP2D6 and CYP2C19 genotypes, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding the CES1 gene and clopidogrel, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding the risk of liver failure associated with Isoniazid in patients with NAT2 *1/*4 genotype, so I am unable to answer this question from the given context.',\n",
       " 'Mutations in the CYP2C9 gene can affect how you should be dosed with warfarin. These mutations can reduce the conversion of warfarin to inactive metabolites, leading to an increased risk of bleeding. \\n\\nPharmacogenetic algorithms can be used to calculate adjusted initial and maintenance doses of warfarin based on the presence of CYP2C9 mutations. This can help to optimize the dose and minimize the risk of bleeding complications.',\n",
       " 'The provided text does not contain any information regarding the effects of CYP2C9 gene variations on the response to Mobic or aspirin, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding the specific dosages of tacrolimus prescribed to the donor and the recipient, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding genes associated with amitriptyline, so I cannot answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding the ability of pharmacogenomics to predict side effects of allopurinol.',\n",
       " 'The provided text does not contain any information regarding tacrolimus or CYP3A5 poor metabolizers, so I am unable to answer this question from the given context.',\n",
       " 'The provided text suggests that patients positive for the HLA-B*15:02 allele may be at increased risk of severe skin reactions with phenytoin. Therefore, it is recommended to consider this genetic information when making treatment decisions and potentially adjust the treatment plan accordingly.',\n",
       " 'The provided text does not contain any information regarding G6PD deficiency or rasburicase dosage adjustments, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding pharmacogenetic tests for CAD/Atherosclerotic risk, so I am unable to answer this question from the given context.',\n",
       " \"**Recommendation:**\\n\\nBased on the patient's CYP2D6-Ultra fast Metabolizer status, the current dosage of haloperidol may require adjustment to avoid potential side effects or ineffectiveness.\\n\\n**Action Required:**\\n\\n* **Increase the dosage:**\\n    - The literature suggests that CYP2D6-Ultra fast metabolizers may require a 1.7-fold increase in the standard dose of haloperidol to achieve therapeutic efficacy. \\n    - Consult clinical pharmacology or a pharmacist to determine the appropriate dosage adjustment.\\n\\n\\n* **Consider alternative antipsychotics:**\\n    - Some antipsychotics that are not metabolized by CYP2D6 include citalopram and sertraline.\\n    - These medications may be safer and more suitable for patients with CYP2D6-Ultra fast Metabolizer status.\\n\\n**References:**\\n\\n* Panagiotidis G et al. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome. Ther Drug Monit 2007;29:417-22.\\n* Park JY et al. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. J Clin Psychopharmacol 2006;26:135-42.\\n* LLerena A et al. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients. Pharmacopsychiatry 2004;37:69-73.\\n* Desai M et al. Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. Pharmacogenomics J 2003;3:105-13.\",\n",
       " 'The provided text does not contain any information regarding the effect of CYP2D6 Poor Metabolizer on the dosage of codeine, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain information regarding the consequence of a *1 *15 genotype in SLCO1B1 for simvastatin use, so I am unable to answer this question from the given context.',\n",
       " '**Yes, you should modify his existing prescription.**\\n\\n- **CYP2D6 intermediate metabolizers:** Consider reducing the starting dose of amitriptyline by at least one level and monitor for adverse reactions.\\n- **CYP2C19 poor metabolizers:** Reduce the dosage of amitriptyline based on individual patient tolerance.',\n",
       " \"**Step 1: Review the Patient's Medical History and Current Medications**\\n\\n* Gather information about the patient's overall health, other medications, and any relevant genetic or medical factors.\\n* Assess the patient's current symptoms and treatment goals.\\n\\n\\n**Step 2: Interpret the Pharmacogenetic Results**\\n\\n* Understand the significance of the CYP2C19-Ultra Rapid Metabolizer phenotype.\\n* Review the provided CPIC, FDA, and PGKB recommendations for escitalopram dosage adjustments in CYP2C19 intermediate metabolizers.\\n\\n**Step 3: Consider the Patient's Individual Circumstances**\\n\\n* Consider the patient's age, weight, and other clinical factors.\\n* Evaluate the patient's risk-benefit ratio for dose adjustment.\\n\\n**Step 4: Tailor the Treatment Plan**\\n\\n* Based on the patient's individual circumstances and the available recommendations, determine the most appropriate dosage range.\\n* Start with a lower dose within the recommended range (10 mg–7.5 mg) and monitor for side effects and efficacy.\\n\\n\\n**Step 5: Monitor and Adjust**\\n\\n* Regularly monitor the patient's response to treatment, including side effects and clinical outcomes.\\n* Consider dose adjustments based on clinical monitoring and feedback from the patient.\\n\\n\\n**Additional Considerations:**\\n\\n* Communicate the importance of adhering to medical advice and following dose recommendations.\\n* Provide information about potential side effects and how to manage them.\\n* Collaborate with healthcare providers experienced in pharmacogenetics for guidance and interpretation of the results.\",\n",
       " 'The provided text does not contain any information regarding PGx tests for assessing antibiotic resistance or managing recurrent UTIs, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding medications or dosages for colorectal cancer treatment in patients with a UGT1A1 *1/*28 diplotype or their interaction with atazanavir, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding guidelines for managing the risk of adverse responses to Anti Neo plastic based on patient morphologies. Therefore, I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding therapeutic guidelines for modifying the use of analgesics in response to pharmacogenomic testing, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain information regarding the recommended dosage of pimozide for a patient with CYP2D6 *3/*3 diplotype, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain information regarding the standard guidelines for using \"ivacaftor\" in individuals with the latest version of the guidelines and individual patient data from the provided.',\n",
       " 'The provided text suggests requesting a **NUDT15 genotype test** to mitigate the risk of immunological suppression associated with azathioprine therapy.\\n\\n**Suggested pharmacogenetic panels or assays:**\\n\\n* Comprehensive pharmacogenetic panels that include NUDT15 gene analysis.\\n* Specific NUDT15 assays, such as:\\n    * Co-occurrence of TPMT and NUDT15 mutations\\n    * NUDT15 alleles associated with impaired metabolism\\n\\n**Additional considerations:**\\n\\n* The test should be performed before initiating azathioprine therapy.\\n* The results of the test should be interpreted by a qualified pharmacogeneticist to determine the appropriate dose adjustment and risk management strategies.',\n",
       " 'The provided text does not contain any information regarding HLA-A*31:01 and HLA-B*15:02 tests or their usefulness in relation to anticonvulsant-induced DRESS, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding medications or dosages for fungal infections in patients with DPYD, so I am unable to answer this question from the given context.',\n",
       " \"Based on the provided information, your patient's SLCO1B1 genotype suggests a decreased function phenotype, which increases the risk of statin-induced myopathy. Therefore, continuing atorvastatin therapy without modifications is not recommended.\\n\\n**Recommendations:**\\n\\n* **Consider changing the statin:**\\n    - Opt for an alternative statin not primarily metabolized by CYP2C9, such as pravastatin or rosuvastatin.\\n    - Consult relevant clinical guidelines for specific recommendations.\\n\\n* **Dose adjustment:**\\n    - Consult with a healthcare professional to determine an appropriate dose reduction for fluvastatin, if applicable.\\n    - Close monitoring for side effects is essential.\\n\\n**Relevant References:**\\n\\n* **Pharmacogenomics and Drug Safety:** https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling\\n* **PharmGKB Statin Gene Variants:** https://www.pharmgkb.org/chemical/PA449688/clinicalAnnotation\\n* **Dutch Pharmacogenetic Database (DPWG):** https://www.knmp.nl/patientenzorg/medicatiebewaking/farmacogenetica/pharmacogenetics-1/pharmacogenetics\\n\\n**Additional Notes:**\\n\\n* The provided text does not include specific dosing recommendations for statins based on SLCO1B1 genotypes. Therefore, consult with a healthcare professional for personalized guidance.\\n* Always refer to reliable sources of information such as official guidelines and peer-reviewed publications for the most up-to-date evidence-based recommendations.\",\n",
       " 'The provided text does not contain any information regarding interactions between the VKORC1, CYP2C19, and CYP2C9 genes and anticoagulant therapy, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding the standard guidelines for immunosuppressive medication use in patients whose CYP3A5, NUDT15, and TPMT genotypes indicate poor or diminished function, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding recognized clinical methods for modifying antiviral therapy based on IFNL3, UGT1A1, HLA-B*57:01, or CYP2B6 genotypes, so I am unable to answer this question from the given context.',\n",
       " '**Value of SLCO1B1 testing:**\\n\\nSLCO1B1 testing and clinical management of statin',\n",
       " 'The provided text does not contain information regarding specific guidelines for managing the risk of adverse responses to analgesics depending on patient phenotypes, or the influence of CYP2D6 and CYP2C9 phenotypes on this risk.',\n",
       " '**Importance of Considering Patient-Specific Characteristics with PGx Testing Results:**\\n\\n**1. HLA-B*15:02 and HLA-A*31:01:**\\n\\n- PGx testing reveals an association between HLA-B*15:02 and HLA-A*31:01 alleles and adverse reactions to carbamazepine (CBZ).\\n- In patients with these alleles, alternative medications should be considered as first-line therapy to avoid potential hypersensitivity reactions.\\n\\n\\n**2. CYP2C9:**\\n\\n- CYP2C9 genotype information can provide insights into drug metabolism.\\n- For patients with a \"None\" phenotype for CYP2C9, the exact impact on fluvastatin metabolism is uncertain.\\n- Close monitoring and dose adjustments may be necessary to optimize therapy.\\n\\n\\n**3. Patient-Specific Characteristics:**\\n\\n- Genetic testing results should be interpreted in the context of the patient\\'s individual characteristics, including age, sex, medical history, and co-existing medications.\\n- Factors such as underlying health conditions, ethnicity, and diet can influence drug metabolism and response.\\n\\n\\n**Considerations for Clinical Decision-Making:**\\n\\n- **Individualized Treatment Plans:** PGx testing results should guide tailored treatment plans, considering patient-specific characteristics and potential drug-gene interactions.\\n- **Alternative Medications:** In patients with HLA-B*15:02 or HLA-A*31:01, alternative medications should be preferentially selected to minimize the risk of CBZ hypersensitivity.\\n- **Dose Adjustments:** For patients with CYP2C9 variations, dose adjustments or monitoring may be necessary to optimize drug efficacy and safety.\\n- **Comprehensive Evaluation:** PGx testing results should be interpreted alongside clinical evaluation, including symptoms, medical history, and other laboratory findings.\\n\\n\\n**Benefits of Considering Patient-Specific Characteristics:**\\n\\n- Improved drug safety and efficacy by identifying potential drug-gene interactions.\\n- Personalized treatment recommendations based on individual characteristics.\\n- Reduced risk of adverse drug reactions and improved patient outcomes.',\n",
       " '**Recommendation:**\\n\\n- Reduce the dose of flecainide to 75% of the standard dose.\\n- Record an ECG and monitor the plasma concentration.\\n- Consider performing a provocation test for diagnosis of Brugada syndrome.\\n- At a dose of 2.0 mg.',\n",
       " 'The provided text does not contain any information regarding the management of patients taking arpriprazole in combination with Celecoxib, so I am unable to answer this question from the given context.',\n",
       " \"**Impact of CYP2C19's Ultra Rapid Metabolizer on Citalopram Dosage:**\\n\\n- CYP2C19 is involved in the metabolism of citalopram.\\n- Ultrarapid metabolizers break down the drug more quickly, potentially leading to lower levels of the drug in the body and reduced effectiveness.\\n\\n\\n**Ideal Dosage:**\\n\\n- The recommended starting dose for citalopram should be adjusted for individuals with CYP2C19 ultrarapid metabolism.\\n- Consider a 100% increase in the standard dose, but do not exceed the maximum recommended dose.\\n\\n\\n**Effects of Other Drugs, Medical Conditions, and Circumstances:**\\n\\n- **Other drugs:** Some medications metabolized by CYP2C19 may interact with citalopram.\\n- **Medical conditions:** Underlying health issues can influence the metabolism and efficacy of citalopram.\\n- **Lifestyle factors:** Diet, alcohol consumption, and smoking habits can affect the drug's metabolism.\\n\\n\\n**Considerations:**\\n\\n- Close monitoring of symptoms, side effects, and drug concentrations is essential to determine the optimal dose.\\n- Alternative antidepressants not metabolization.\\n\\n\\n**Disclaimer: The information provided is for reference.\",\n",
       " 'The provided text does not contain information regarding PGx recommendations for children prescribed Hypoglycemics, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding medication recommendations or dosage adjustments for tropisetron in the context of CYP2D6-Ultra fast Metabolizer patients, so I am unable to answer this question from the given context.',\n",
       " '## Dosage Adjustment Recommendations:\\n\\n**Based on the provided PGx results:**\\n\\n* **TPMT:** Intermediate Metabolizer\\n* **NUDT15:** Poor Metabolizer\\n\\n**Recommendations:**\\n\\n* **Reduce the thioguanine dose by approximately 70%** compared to the standard dose. \\n* Close monitoring of blood counts is essential to assess for potential myelosuppression.\\n* Consider dose adjustments based on efficacy as needed.\\n\\n**Justification:**\\n\\n* The provided text suggests that TPMT and NUDT15 gene variations can increase the concentration of the fully activated metabolite of thioguanine, leading to a higher risk of myelosuppression.\\n* For TPMT intermediate metabolizers, a dose reduction of approximately 70% is recommended.\\n* For NUDT15 poor metabolizers, insufficient data are available to provide a specific dose reduction recommendation, but a general reduction of 70% is suggested as a starting point.\\n\\n**Additional Considerations:**\\n\\n* More stringent dose reductions may be necessary if the patient also has TPMT IM or TPMT PM variations.\\n* The provided text suggests that dose adjustment based on total 6-TGN metabolites is not appropriate for patients with these gene variants.\\n\\n**References:**\\n\\n* FDA Labeling: https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling\\n* PharmGKB: https://www.pharmgkb.org/chemical/PA450379\\n\\n**Note:** The provided text does not contain information regarding alternative anti-neoplastic agents for TPMT/NUDT15 gene variations. Further consultation with a healthcare professional or oncologist is recommended for recommendations regarding different treatment options.',\n",
       " 'The provided text does not contain any information regarding the effect of antifungal drugs on the DPYD gene, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain information regarding CYP2C9 pharmacogenomic variables that matter when administering NSAIDS, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding CFTR mutations and their influence on therapy selection in Cystic fibrosis patients, so I am unable to answer this question from the given context.',\n",
       " \"The provided text does not contain any information regarding the effects of gene variations CYP2C19 and CYP2D6 on the body's reaction to tricyclic antidepressants, so I am unable to answer this question from the given context.\",\n",
       " '**Recommendation:**\\n\\nClopidogrel may not be effective or may increase the risk of adverse cardiovascular events in patients with CYP2C19*3/*3 status.\\n\\n**Sources:**\\n\\n* Wu Y et al. Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy. Pharmacogenomics J 2018;18:713-20.\\n* Cavallari LH et al. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interv 2018;11:181-91.\\n* Pan Y et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Circulation 2017;135:21-33.',\n",
       " 'The provided text does not contain any information regarding the relevance of NAT2 testing in pediatric populations, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding the role of CYP2B6 genotyping in methadone treatment, so I am unable to answer this question from the given context.',\n",
       " 'nan',\n",
       " 'The provided text does not contain any information regarding the safety of streptomycin and tobramycin in the pediatric population, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding the effect of CYP2C19 metabolism on clopidogrel, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding ACE polymorphisms and their effect on ACE inhibitor response, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding the prediction of transtumab response, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding the connection between HLAB1502 and Steven Johnson syndrome, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding HIV patients on efavirenz and the risk of long QT syndrome or how genetics can alter dosing, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain information regarding ivacaftor dosage recommendations based on CFTR genotypes, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain information regarding tacrolimus dosage recommendations or CYP3A5*3/*3 diplotype, so I am unable to answer this question from the given context.',\n",
       " \"The patient's CYP3A4 *6/*8 genotype suggests that he is a poor metabolizer of certain medications, including clomipramine. \\n\\n**Potential risks associated with clomipramine in patients with CYP3A4 deficiency:**\\n\\n- Increased risk of side effects due to accumulation of clomipramine and its active metabolite desmethylclomipramine.\\n- Higher risk of clomipramine toxicity, with plasma concentrations above 600 ng/mL considered toxic.\\n\\n**Recommendations:**\\n\\n- Avoid clomipramine due to the potential for severe side effects and toxicity.\\n- Consider alternative antidepressants that are not metabolized by CYP3A4, such as citalopram or sertraline.\\n\\n**Supporting Resources:**\\n\\n- Vos A et al. Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics J 2011;11:359-67.\\n- Stephan PL et al. Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP3A4/5 activity. Pharmacopsychiatry 2006;39:150-2.\",\n",
       " 'The provided text does not contain any information regarding guidelines for SLCO1B1 *5/*7 for atorvastatin use, so I am unable to answer this question from the given context.',\n",
       " '**Azathioprine and NUDT15 Diplotype:**\\n\\n- Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day.\\n- Adjust doses based on degree of myelosuppression and disease-specific guidelines.\\n- Allow 2-4 weeks to reach steady-state after each dose adjustment.\\n\\n\\n**Azathioprine and TPMT Diplotype:**\\n\\n- TPMT status is critical in guiding azathioprine dosing.\\n- Determine TPMT metabolizer status.\\n- Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype.\\n- If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.',\n",
       " 'The provided text does not contain any information regarding Flurbiprofen dosage recommendations for CYP2C9 poor metaboliser, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding specific recommendations or treatment strategies for managing the risk of thrombosis in patients with rs6025 TT genotype on oral contraceptive pills. Therefore, I am unable to answer this question from the given context.',\n",
       " \"The provided text does not contain any information regarding pharmacogenomics recommendations for amitriptyline in the context of depression and early onset Parkinson's disease, so I am unable to answer this question from the given context.\",\n",
       " 'The provided text does not contain any information regarding the guideline for rs1801133 AA status for methotrexate administration, so I am unable to answer this question from the given context.',\n",
       " '**Guidelines for capecitabine dosage and DPYD genotypes:**\\n\\n**For DPYD Poor Metabolizers:**\\n\\n* Avoid the use of capecitabine or 5-fluorouracil-based regimens.\\n* Consider alternative chemotherapy treatment options.\\n* If capecitabine treatment is absolutely necessary:\\n    * Start with a significant initial dose reduction (e.g., by 50%).\\n    * Closely monitor for severe or life-threatening side effects.\\n    * Consider intensive monitoring for gastrointestinal symptoms, neutropenia, and skin reactions.\\n\\n**Dose adjustment recommendations:**\\n\\n* Determine the residual DPD activity in mononuclear cells from peripheral blood.\\n* Adjust the initial dose based on phenotype and genotype.\\n* Avoid tegafur as it is also metabolized by DPD.\\n\\n**Official DPWG Recommendation:**\\n\\n* Reduce the standard dose of capecitabine by 50% or more.\\n* Monitor the dose after titration based on toxicity and effectiveness.\\n* In some cases, determine the residual DPD activity in mononuclear cells and adjust the initial dose adjustment.\\n\\n**',\n",
       " 'The provided text does not contain any information regarding codiene prescription in pediatric population or the essential genes to be tested, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding the safety of starting phenobarbital and carbamazepine together in a 3-year-old patient with tonic clonic seizures. Therefore, I am unable to answer this question from the given context.',\n",
       " \"**Step 1: Review the patient's medical history and current medications.**\\n\\n* Assess the patient's cardiovascular risk factors and the potential benefits of clopidogrel.\\n* Review any other medications they are taking that may interact with clopidogrel.\\n\\n\\n**Step 2: Consult with a healthcare provider experienced in pharmacogenomics, cardiology, or hematology.**\\n\\n* Discuss the patient's CYP2C19 genotype and its potential impact on clopidogrel metabolism.\\n* Obtain recommendations on dosage adjustments or alternative therapies.\\n\\n\\n**Step 3: Consider alternative therapies.**\\n\\n* Explore other antiplatelet medications that have different CYP2C19 metabolism pathways.\\n* Evaluate the risks and benefits of different options carefully.\\n\\n\\n**Step 4: Close monitoring and patient education.**\\n\\n* Monitor the patient's platelet function and clinical response to clopidogrel.\\n* Educate the patient about the potential risks of bleeding and the importance of seeking medical attention if symptoms arise.\\n\\n\\n**Step 5: Personalized approach.**\\n\\n* Consider other factors such as the patient's overall health, other medications, lifestyle, and preferences when making treatment decisions.\",\n",
       " 'The provided text does not contain any information regarding dosage recommendations or considerations for tacrolimus, so I am unable to answer the question from the given context.',\n",
       " 'The provided text does not contain any information regarding CFTR alleles and their influence on ivacaftor response, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding the effect of CYP3A4/CYP3A5 status on tacrolimus dosage, so I am unable to answer this question from the given context.',\n",
       " '## Guidelines for Ariprazole and Amitriptyline in CYP2C19 Poor and CYP2D6 Intermediate Metaboliser:\\n\\n**Ariprazole:**\\n\\n* Due to impaired metabolism, a lower dose is recommended:\\n    * Start with 2.5 mg once daily.\\n    * Monitor for side effects and efficacy before increasing the dose.\\n    * Consider alternative formulations like the injectable, which may achieve therapeutic concentrations with lower doses.\\n\\n**Amitriptyline:**\\n\\n* Dose adjustment is required:\\n    * Start with a lower dose of 25 mg daily.\\n    * Gradually increase the dose by 25 mg every 2-3 days, while monitoring for side effects.\\n    * The final dose should be individualized based on therapeutic response and side effect profile.\\n\\n**Additional Considerations:**\\n\\n* Close monitoring of side effects is essential during treatment initiation and dose adjustment.\\n* Regular monitoring of serum concentrations of both medications can help guide dose adjustment and ensure therapeutic efficacy.\\n* Consider other factors like age, diet, and co-administered medications when adjusting the dose.\\n* Consult with a healthcare professional experienced in managing complex medication interactions.',\n",
       " \"## For MTHFR C677T heterozygous:\\n\\n**1. Regular folic acid can definitely help in subsequent pregnancies:**\\n\\n- Folic acid has been shown to reduce the risk of neural tube defects in fetuses by up to 70% in women with MTHFR C677T genotype.\\n- Recommended dosage is 400mg folic acid daily from conception until 12 weeks of gestation.\\n\\n**2. Additional considerations:**\\n\\n- Lifestyle modifications like healthy diet rich in folate, limiting caffeine and alcohol consumption, and avoiding smoking are also important.\\n- Genetic counseling is recommended to assess the risk of other genetic factors that could contribute to miscarriage.\\n\\n\\n## For rheumatoid arthritis and methotrexate:\\n\\n**1. Methotrexate may be beneficial:**\\n\\n- Studies suggest that methotrexate can reduce the risk of miscarriage in women with rheumatoid arthritis.\\n- It is often used as part of the treatment for rheumatoid arthritis alongside other medications like hydroxychloroquine.\\n\\n**2. Relevant factors to consider:**\\n\\n- Methotrexate can cause side effects like nausea, vomiting, bone marrow suppression, and gastrointestinal problems.\\n- It is crucial to monitor blood counts and liver function while taking methotrexate.\\n- The effectiveness of methotrexate in preventing miscarriage may depend on the individual's disease severity and other underlying factors.\\n\\n\\n**Recommendations:**\\n\\n- Consult with a healthcare professional to determine the most appropriate treatment options for rheumatoid arthritis based on individual needs and medical history.\\n- Discuss the potential risks and benefits of methotrexate with your doctor.\\n- Continue folic acid supplementation as recommended.\\n\\n**Additional suggestions:**\\n\\n- Consider seeking support groups or working with a fertility counselor to address the emotional impact of previous miscarriage and manage future pregnancy anxieties.\\n- Maintain a healthy lifestyle with a balanced diet, regular exercise, and adequate sleep to support overall well-being.\",\n",
       " 'The provided text does not contain any information regarding the recommendation for patient with dyslipidemia and gastric cancer, Patient is SLCO1B1 poor metaboliser and DPYD intermediate metaboliser, for atorvastatin and capecitabine, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding the role of COMT and CYP2D6 variations in addiction of antipschotropics, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain information regarding the recommended dosage of fluvastatin for a patient with CYP2C9 poor and SLCO1B1 normal metabolism.',\n",
       " 'The provided text does not contain any information regarding how to plan mercaptopurine dosage in NUDT intermediate and TPMT poor metabolism patients, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding the influence of CYP2C19 and CYP2D6 on doxepin metabolism, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding the safety of warfarin prescription in patients with an unavailable VKORC1 genotype and normal CYP2C9 metabolism, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding rs121434568 and its determination of geftinib response in small cell lung carcinoma patients, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding prescribing sertraline for a patient with CYP2B6*4/*9 diplotype, so I am unable to answer this question from the given context.',\n",
       " 'The provided text does not contain any information regarding the importance of HLA status for phenytoin metabolism, so I cannot answer this question from the given context.',\n",
       " \"The provided text suggests that due to the patient's CYP2D6 poor metabolism, ondansetron is not suitable. The suggested alternatives that do not depend on CYP2D6 metabolism are:\\n\\n- Morphine\\n- Oxycodone\",\n",
       " 'Patients with DPYD poor metabolism of fluorouracil are at an increased risk of severe side effects, including:\\n\\n- Severe 5-fluorouracil (5-FU)-related toxicity\\n- Life-threatening toxicity\\n- Potentially fatal toxicity',\n",
       " 'The provided text does not contain any information regarding pharmacogenomic panel recommendations for a patient with T2DM, hypertension, and colorectal cancer, so I am unable to answer this question from the given context.']"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "list(map(str, quests[\"gemma_resp\"].to_list()))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# To dict\n",
    "data = {\n",
    "    \"question\": list(map(str, quests[\"Questions\"].to_list())),\n",
    "    \"answer\": list(map(str, quests[\"llama2_resp\"].to_list())),\n",
    "    \"contexts\": [[str(context)] for context in quests[\"context\"].to_list()],\n",
    "    \"ground_truth\": list(map(str, quests[\"Expected_response\"].to_list()))\n",
    "}\n",
    "\n",
    "# Convert dict to dataset\n",
    "dataset = Dataset.from_dict(data)\n",
    "\n",
    "result = evaluate(\n",
    "    dataset = dataset, \n",
    "    metrics=[\n",
    "        context_entity_recall,\n",
    "        context_precision,\n",
    "        context_recall,\n",
    "        faithfulness,\n",
    "        answer_relevancy,\n",
    "        answer_similarity,\n",
    "        answer_correctness,\n",
    "        harmfulness\n",
    "    ],\n",
    "    llm = llm,\n",
    "    embeddings= embeddings\n",
    ")\n",
    "df = result.to_pandas()\n",
    "df.to_csv(\"/home/dhanushb/Wellytics/RAG_data/results/llama2_eval.csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# To dict\n",
    "data = {\n",
    "    \"question\": list(map(str, quests[\"Questions\"].to_list())),\n",
    "    \"answer\": list(map(str, quests[\"llama3_resp\"].to_list())),\n",
    "    \"contexts\": [[str(context)] for context in quests[\"context\"].to_list()],\n",
    "    \"ground_truth\": list(map(str, quests[\"Expected_response\"].to_list()))\n",
    "}\n",
    "\n",
    "# Convert dict to dataset\n",
    "dataset = Dataset.from_dict(data)\n",
    "\n",
    "result = evaluate(\n",
    "    dataset = dataset, \n",
    "    metrics=[\n",
    "        context_entity_recall,\n",
    "        context_precision,\n",
    "        context_recall,\n",
    "        faithfulness,\n",
    "        answer_relevancy,\n",
    "        answer_similarity,\n",
    "        answer_correctness,\n",
    "        harmfulness\n",
    "    ],\n",
    "    llm = llm,\n",
    "    embeddings= embeddings\n",
    ")\n",
    "df = result.to_pandas()\n",
    "df.to_csv(\"/home/dhanushb/Wellytics/RAG_data/results/llama3_eval.csv\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "AIdemo",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
